Tricyclic boronic acid derivatives and their preparation and use

Novel compounds represented by formula (I) serve as effective β-lactamase inhibitors, addressing the issue of drug-resistant bacteria by enhancing the efficacy of β-lactam antibiotics against MBL-producing strains, thereby combating multidrug-resistant infections.

JP2024540953AActive Publication Date: 2024-11-06SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024523711
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-13
Filing Date
2022-10-19
Publication Date
2024-11-06
Estimated Expiration
2042-10-19

AI Technical Summary

Technical Problem

The rapid emergence of drug-resistant bacteria, particularly those producing metallo-β-lactamases (MBL), has rendered current β-lactamase inhibitors ineffective, posing a significant threat to global health and necessitating new antimicrobials to combat multidrug-resistant bacteria.

Method used

Development of novel compounds represented by formula (I) and their optical isomers and pharmaceutically acceptable salts, which act as potent β-lactamase inhibitors, capable of overcoming MBL-mediated resistance by effectively inhibiting β-lactamases.

Benefits of technology

These compounds enhance the efficacy of β-lactam antibiotics against drug-resistant bacteria, including those producing MBL, thereby expanding the antibacterial spectrum and reducing resistance, thus providing a critical solution to the growing challenge of bacterial drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540953000001_ABST
    Figure 2024540953000001_ABST
Patent Text Reader

Abstract

The present invention discloses tricyclic boronic acid derivatives and their preparation and use, and in particular, discloses a compound represented by formula (I), its optical isomers and pharma- ceutically acceptable salts, as well as the use of said compounds as β-lactamase inhibitors and compositions as antibacterial medicaments. JPEG2024540953000125.jpg2950
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention belongs to the field of medicinal chemistry, and specifically relates to a compound represented by formula (I), its optical isomers and pharma- ceutically acceptable salts thereof, as well as the use of the compound as a β-lactamase inhibitor and the composition as an antibacterial medicament. [Background technology]

[0002] This application claims priority to: CN202111217905.0, the filing date is October 19, 2021; CN202211255968.X, application date is October 13, 2022.

[0003] Due to the widespread use and overuse of antibiotics, pathogenic bacteria have rapidly evolved the ability to resist antimicrobial drugs, resulting in the creation of numerous drug-resistant, multi-drug-resistant, and even superbugs. Bacterial drug resistance has become a major challenge to global public health. According to the 2014 Review on Antimicrobial Resistance, 700,000 people currently die from antibiotic resistance every year. China's bacterial resistance rate is much higher than that of Western countries, at about 45%. More than 80,000 people die from drug-resistant bacterial infections every year in China. If the current situation does not improve and new antibiotics against drug-resistant bacteria do not emerge, it is expected that by 2050, China will experience one million deaths per year and a GDP loss of more than $20 trillion.

[0004] Beta-lactam antibiotics are currently the most important antibacterial drugs in clinical practice, accounting for more than 50% of the total market. Beta-lactam antibiotics refer to a large class of antibiotics that have a beta-lactam ring in their chemical structure, including the most commonly used penicillins and cephalosporins, as well as other atypical beta-lactam antibiotics such as carbapenems and monocyclic beta-lactams. This type of antibiotic has the advantages of strong bactericidal activity, low toxicity, wide range of indications and excellent clinical efficacy. The mechanism of action of beta-lactam antibiotics is similar, inhibiting cell wall mucin synthesis enzymes, i.e. penicillin-binding proteins, thereby inhibiting the synthesis of cell wall mucin, causing bacterial cell wall defects, swelling and lysis of bacterial cells.

[0005] One of the main mechanisms of bacterial resistance to β-lactam antibiotics is the production of β-lactamases. More than 2,800 β-lactamases have been reported so far. They differ in many aspects, such as source, substrate, inhibitor, and structure. In 1980, Ambler classified β-lactamases into four categories according to their molecular structure based on amino acid sequence analysis: Category A penicillinases, Category B metallo-β-lactamases, Category C cephalosporinases, and Category D oxacillinases. Here, the active groups of categories A, C, and D are serine (SBL), and category B is metallic zinc ion (MBL).

[0006] β-lactamase inhibitors can bind to β-lactamase and inactivate the enzyme. Clinically, when combined with β-lactam antibiotics, they can inhibit drug-resistant bacteria, reduce the dosage, expand the antibacterial spectrum, and enhance antibacterial activity. To date, there are six types of β-lactamase inhibitors approved by the FDA, but all of them have significant limitations and cannot effectively treat MBL-mediated superbug resistance. Clavulanic acid, sulbactam, and tazobactam only inhibit some class A SBLs, and avibactam inhibits class A, C, and D SBLs, but is ineffective against pathogenic bacteria resistant to MBL. MBL can hydrolyze all β-lactam antibiotics except monocyclic β-lactams, including penicillins, cephalosporins, extended-spectrum cephalosporins, and carbapenems. According to the China Bacterial Resistance Surveillance Network (CHINET), among the strains clinically isolated in China in 2018, resistance to carbapenem antibiotics such as meropenem in Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter reached 26.3%, 25.8% and 73.9%, respectively, among which the resistance rate of Klebsiella pneumoniae to meropenem increased from 2.9% in 2005 to 26.3%, and the resistance rate of Acinetobacter baumannii increased from 41.3% in 2005 to 73.9%. Acinetobacter baumannii has a strong ability to acquire drug resistance and spread clonally, and has evolved into an important pathogen in hospital-acquired infections. In the WHO priority list for the development of effective drugs against antibiotic-resistant bacteria, carbapenem-resistant Acinetobacter baumannii is ranked at a very high priority. Carbapenems are the last line of defense against bacterial infections, and when drug resistance occurs, the options available are very limited and in some cases unavailable. Therefore, there is an urgent clinical need for new antibacterial agents to overcome the treatment dilemma and solve the increasingly prominent challenge of drug resistance.

[0007] There are many mechanisms of bacterial resistance, which can be summarized as follows: (1) Changes in the permeability of the bacterial cell wall or outer membrane, such as a decrease in the expression of porins and an increase in the expression of efflux pumps, make it impossible or almost impossible for bacteria to enter the bacterial body and reach the target site of action, and the outer membrane of Gram-negative bacteria is the first barrier that limits the penetration of β-lactam antibiotics into the bacterial body; (2) Mutations in the target protein lead to a decrease in binding to the antibiotic, an increase in the target protein, or the production of a new target protein. For example, methicillin-resistant Staphylococcus aureus shows high resistance because a new PBP2' is generated between the original PBP2 and PBP3, while low and moderate resistance is caused by an increase in the production of PBPs or a decrease in affinity for methicillin; (3) Bacteria produce β-lactamase to hydrolyze and inactivate the antibiotic, or bind to the antibiotic and remain in the extracellular space, making it unable to enter the cell and bind to the target protein. The main resistance mechanism for Gram-positive bacteria is the production of β-lactamases and PBP mutations, whereas the main resistance mechanism for Gram-negative bacteria is the production of β-lactamases. Summary of the Invention

[0008] In a first aspect, the present invention provides a compound represented by formula (I), an optical isomer thereof, and a pharma- ceutically acceptable salt thereof. [ka] Where: X is selected from S, S(=O) and S(=O)2; L1 is a single bond, C 1-6 Alkyl and C 1-6 heteroalkyl, 1-6 Alkyl or C 1-6 The heteroalkyl is optionally substituted by 1, 2 or 3 R; L2 is a single bond, C 3-6 cycloalkyl and 4- to 9-membered heterocycloalkyl; 3-6cycloalkyl or 4- to 9-membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R; L3 is a single bond, C 1-6 Alkyl, C 1-6 heteroalkyl and 4- to 9-membered heterocycloalkyl; 1-6 Alkyl, C 1-6 heteroalkyl or 4- to 9-membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R; R1 is NH2, [ka] , -NR a C(=NH)R b , -NR a C(=NH)NR b1 R b2 , -C(=NH)R b , C 1-6 Alkyl, C 3-6 cycloalkyl, 4- to 8-membered heterocycloalkyl, partially unsaturated 4- to 8-membered heterocycloalkyl, and 5- to 6-membered heteroaryl, 1-6 Alkyl, C 3-6 Cycloalkyl, 4- to 8-membered heterocycloalkyl, partially unsaturated 4- to 8-membered heterocycloalkyl or 5- to 6-membered heteroaryl are optionally substituted by 1, 2 or 3 R; R, R a , R b , R b1 , R b2 are independently H, F, Cl, Br, OH, NH2, CN, and C 1-6 Alkyl and C 3-6 cycloalkyl, 1-6 Alkyl or C 3-6 Cycloalkyl is optionally substituted by 1, 2 or 3 R'; R' is independently selected from F, Cl, Br, I, NH2, OH, and Me; Said C 1-6Heteroalkyl, 4- to 9-membered heterocycloalkyl, partially unsaturated 4- to 8-membered heterocycloalkyl, or 5- to 6-membered heteroaryl contain one, two, or three heteroatoms or heteroatomic groups independently selected from O, NH, S, C(=O), C(=NH), C(=O)O, S(=O), S(=O)2, and N.

[0009] In some embodiments of the present invention, the compound represented by formula (I), its optical isomer, and its pharma- ceutically acceptable salt are selected from the compounds represented by formulas (IA) and (IB), their optical isomers, and their pharma- ceutically acceptable salts. [ka] Where: X, L1, L2, L3 and R1 are as defined above. In some embodiments of the invention, each R is independently selected from R and is F, Cl, Br, OH, NH, CH, [ka] wherein CH3, [ka] is optionally substituted by 1, 2 or 3 R', and the remaining variables are as defined herein.

[0010] In some embodiments of the invention, R is independently F, Cl, Br, OH, NH2, CH3, [ka] and the remaining variables are as defined herein.

[0011] In some embodiments of the present invention, L is a single bond, C 1-3 Alkyl, -C 1-3 Alkyl-O-, -C1-3 Alkyl-S-, -C 1-3 Alkyl-NH- and -C 1-3 alkyl-C(=O)-, 1-3 Alkyl, -C 1-3 Alkyl-O-, -C 1-3 Alkyl-S-, -C 1-3 Alkyl-NH- or -C 1-3 The alkyl-C(=O)- is optionally substituted with 1, 2 or 3 R, and the remaining variables are as defined herein.

[0012] In some embodiments of the present invention, L1 is a single bond, CH2, [ka] wherein CH2, [ka] is optionally replaced by 1, 2 or 3 R, and the remaining variables are as defined herein.

[0013] In some embodiments of the present invention, L1 is a single bond, CH2, [ka] and the remaining variables are as defined herein.

[0014] In some embodiments of the invention, L2 is selected from a single bond, cyclobutyl, cyclopentyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, and 2,6-diazaspiro[3.3]heptyl, wherein said cyclobutyl, cyclopentyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, or 2,6-diazaspiro[3.3]heptyl is optionally substituted by one, two, or three R, and the remaining variables are as defined herein.

[0015] In some embodiments of the invention, L2 is a single bond, [ka] and the remaining variables are as defined herein.

[0016] In some embodiments of the present invention, L3 is a single bond, C(=O), C 1-3 Alkyl, -C 1-3 Alkyl-C(=O)- and -C 1-3 alkyl-C(=O)NH-, 1-3 Alkyl, -C 1-3 Alkyl-C(=O)- or -C 1-3 The alkyl-C(=O)NH- is optionally substituted with 1, 2 or 3 R, and the remaining variables are as defined herein.

[0017] In some embodiments of the present invention, L3 is a single bond, C(=O), [ka] and the remaining variables are as defined herein.

[0018] In some embodiments of the present invention, R1 is NH2, [ka] , C 1-3Alkyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, morpholinyl, piperidinyl, piperazinyl, octahydrocyclopentadiene[c]pyrrolyl, 4,5-dihydro-1H-imidazolyl, imidazolyl, 4,5-dihydro-1H-imidazolyl, imidazoline-2-imino, tetrahydropi imidine-2(1H)-imino, 2,6-diazaspiro[3.3]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octyl, 6-oxa-2-azaspiro[3.4]octyl, 2,6-diazaspiro[3.4]octyl, 3,6-diazabicyclo[3.1.1]heptyl and 2,5-diazabicyclo[2.2.1]heptyl; 1-3 Alkyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, morpholinyl, piperidinyl, piperazinyl, octahydrocyclopentadiene[c]pyrrolyl, 4,5-dihydro-1H-imidazolyl, imidazolyl, 4,5-dihydro-1H-imidazolyl, imidazoline-2-imino, tetrahydropyrimidine-2(1H)-imino, 2,6 -diazaspiro[3.3]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octyl, 6-oxa-2-azaspiro[3.4]octyl, 2,6-diazaspiro[3.4]octyl, 3,6-diazabicyclo[3.1.1]heptyl or 2,5-diazabicyclo[2.2.1]heptyl is optionally substituted by 1, 2 or 3 R, and the remaining variables are as defined herein.

[0019] In some embodiments of the present invention, R1 is NH2, [ka] wherein Me is selected from [ka] is optionally replaced by 1, 2 or 3 R, and the remaining variables are as defined herein.

[0020] In some embodiments of the present invention, R1 is NH2, Me, CF3, [ka] and the remaining variables are as defined herein.

[0021] In some embodiments of the present invention, the structural unit [ka] , Me, CF3, [ka] [ka] and the remaining variables are as defined herein.

[0022] In a second aspect, the present invention also provides a compound of the following formula selected from the following formulae, its optical isomers and pharma- ceutically acceptable salts thereof: [ka] [ka] [ka] [ka]

[0023] In another aspect of the present invention, the present invention also provides compounds of the following formula selected from the following formulae, their optical isomers and pharma- ceutically acceptable salts thereof: [ka] [ka] [ka]

[0024] In a further aspect, the present invention further provides the use of a compound as hereinbefore described, its optical isomers and pharma- ceutically acceptable salts thereof in the manufacture of a medicament for treating a bacterial infection. Some embodiments of the present invention further include combinations of the above-described compounds, their optical isomers, and pharma- ceutically acceptable salts thereof with other β-lactam antibiotics.

[0025] In some embodiments of the invention, the β-lactam antibiotic is selected from penicillins, cephalosporins, carbapenems, monocyclic β-lactam antibiotics, or combinations thereof. In some embodiments of the invention, the penicillin is selected from acid-resistant penicillin, enzyme-resistant penicillin, ampicillin, amoxicillin, pivampicillin, carbenicillin, sulfenicillin, ticarcillin, furbenicillin, azlocillin, and piperacillin.

[0026] In some embodiments of the invention, the cephalosporin is selected from cephalexin, cephradine, cefazolin, cefuroxime, cefamandole, cefaclor, cefotaxime, ceftazidime, ceftriazine, cefoperazone, ceftizoxime, cefepime, cefpirome, and ceftolozane. In some embodiments of the invention, the carbapenem is selected from imipenem, meropenem, panipenem, biapenem, ertapenem, and faropenem. In some embodiments of the invention, the monocyclic β-lactam is selected from aztreonam. <Definitions and Explanations> Unless otherwise explained, the following terms and phrases as used herein are intended to have the following meanings: Certain terms or phrases should not be considered indefinite or uncertain in the absence of a specific definition, but should be understood in their ordinary sense. When trade names are mentioned herein, it is intended to refer to the corresponding product or its active ingredients.

[0027] In the present invention, the phrase "at least one" when used when referring to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but not necessarily including at least one of each of the elements specifically named in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows for the optional presence of elements other than those specifically identified in the list of elements to which the phrase "at least one" refers, whether related to the specifically identified elements or not.

[0028] As used herein, the term "pharmacologically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, may be applied in contact with the tissues of humans and animals and which are free of excessive toxicity, irritation, allergic response or other problem or complication and are commensurate with a reasonable benefit / risk ratio.

[0029] The term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention made with a compound having a specific substituent discovered by the present invention and a relatively non-toxic acid or base. When a compound of the present invention contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of base in a pure solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts. When a compound of the present invention contains a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of acid in a solution or in a suitable inert solvent. Examples of pharma- ceutically acceptable acid addition salts include inorganic acid salts including hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, and the like; and organic acid salts including acetic acid, propionic acid, isobutyric acid, trifluoroacetic acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, and similar acids, further including salts of amino acids (e.g., arginine, etc.) and salts of organic acids such as glucuronic acid. Certain compounds of the present invention contain basic and acidic functional groups and can therefore be converted into any base or acid addition salt.

[0030] The pharma- ceutically acceptable salts of the present invention can be synthesized from a parent compound that contains an acidic or basic group by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in water or an organic solvent, or a mixture of both.

[0031] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, and all such mixtures are included within the scope of the present invention. Other asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers and any mixtures thereof are included within the scope of the invention as claimed.

[0032] The compounds of the present invention may exist in specific forms. Unless otherwise stated, the term "tautomer" or "tautomeric form" refers to isomers of different functional groups that are in dynamic equilibrium at room temperature and can be rapidly interconverted. If tautomers are possible (e.g., in solution), chemical equilibrium of tautomers can be achieved. For example, proton tautomers (also called prototropic tautomers) include interconversions via the transfer of a proton, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions via recombination of some bond electrons. In particular, a specific example of keto-enol tautomerization is the interconversion between the two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.

[0033] The compounds of the present invention may contain unnatural atomic isotopes at one or more atoms that constitute the compounds. For example, the compounds may contain tritium ( 3 H), iodine-125( 125 I), C-14( 14The compound of the present invention may be labeled with a radioisotope such as 1,2-dihydrogen (C), 1,2-dihydrogen (D), 1,2-dihydrogen (H), 1,2-dihydrogen (C), 1,2-dihydrogen (D), 1,2-dihydrogen (H), 1,2-dihydrogen (C), 1,2-dihydrogen (H ...

[0034] " [ka] " The valence bond of the group is marked with a dotted line " [ka] ", the dotted line indicates the point at which the group is attached to the remainder of the molecule. [ka] " for single bonds. [ka] " represents a single bond or the absence of a single bond, and " [ka] " is a single bond " [ka] " or double bond " [ka] " is meant to represent.

[0035] The term "substituted" or "substituted by" refers to the replacement of any one or more hydrogen atoms at a particular atom with a substituent, and may include deuterium and hydrogen variants, provided that the particular valence state is correct and the compound is stable after substitution. The term "optionally substituted" or "optionally substituted by" may or may not be substituted, and unless otherwise defined, the type and number of substituents are any that are chemically stable and feasible.

[0036] When any variable (e.g., R) occurs more than one time in a composition or structure of a compound, its definition is independent at each occurrence. So, for example, if a group is substituted with one, two or three R', then said group is optionally substituted with one, two or three R', and each occurrence of R' is independently optional. Also, combinations of substituents and / or variables thereof are permissible only if such combinations result in stable compounds.

[0037] When one of the variables is a single bond, it indicates that the two groups connected by it are directly linked, for example: [ka] If L1 in represents a single bond, this structure is actually [ka] become.

[0038] If a given substituent does not specify through which atom the substituted substituent is linked, then such substituent may be linked through any atom thereof; for example, a pyridyl group as a substituent may be linked to the substituent through any carbon atom of the pyridine ring.

[0039] If the listed linking group does not specify another linking direction, then the linking direction is arbitrary, for example: [ka] The linking group L in the formula is -CH2O-, where -CH2O- links the phenyl and cyclopentyl in the same direction as reading from left to right. [ka] The phenyl and cyclopentyl groups can be linked in the reverse order of reading from left to right. [ka] Combinations of the above linking groups, substituents and / or variables are permissible only if such combinations result in stable compounds.

[0040] Unless otherwise defined, the number of atoms in a ring is generally defined as the number of ring members, for example, a "3- to 6-membered ring" refers to a "ring" having 3 to 6 atoms arranged around it.

[0041] Unless otherwise defined, "C 1-6 The term "alkyl" refers to a straight or branched chain saturated hydrocarbon group of 1 to 6 carbon atoms. 1-6 Alkyl is C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6 and C5 alkyl, and the like, and may be monovalent (e.g., CH3), divalent (-CH2-) or polyvalent (e.g., [ka] ) may be used. 1-6 Examples of alkyl are CH3, [ka] These include, but are not limited to:

[0042] Unless otherwise defined, the term "C 1-4 "Alkyl" refers to a saturated hydrocarbon group consisting of 1 to 4 carbon atoms in a straight or branched chain. 1-4 Alkyl is C 1-2 , C 1-3 , C 3-4 and C 2-3 alkyl, etc., and may be monovalent (e.g., CH3), divalent (-CH2-) or polyvalent (e.g., [ka] ) can be. C 1-4 Examples of alkyl are CH3, [ka] These include, but are not limited to:

[0043] Unless otherwise defined, the term "heteroalkyl," by itself or in combination with other terms, refers to a stable linear or branched alkyl group or combinations thereof consisting of the specified number of carbon atoms and at least one heteroatom or heteroatom group. In some embodiments, the heteroatom is selected from B, O, N, and S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen heteroatom is optionally quaternized. In other embodiments, the heteroatom group is selected from -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O), -S(=O)2-, -C(=O)N(H)-, -N(H)-, -C(=NH)-, -S(=O)2N(H)-, and -S(=O)N(H)-. In some embodiments, the heteroalkyl is selected from C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)-, -C(=O)N(H)-, -C(=NH)-, -S(=O)N(H)-, and -S(=O)N(H)-. 1-6 heteroalkyl, in another embodiment, the heteroalkyl is C 1-3Although the heteroatom or heteroatom group can be placed at any interior position of the heteroalkyl, including the position at which the alkyl is attached to the remainder of the molecule, the term "alkoxy" is a convention and refers to an alkyl attached to the remainder of the molecule via an oxygen atom. Examples of heteroalkyl include, but are not limited to, -OCH, -OCHCH, -OCHCHCH, -OCH(CH), -CH-CH-O-CH, -NHCH, -N(CH), -NHCHCH, -N(CH)(CHCH), -CH-CH-NH-CH, -CH-CH-N(CH)-CH, -SCH, -SCHCH, -SCHCHCH, -SCH(CH), -CH-S-CH-CH, -CH-CH, -S(=O)-CH, -CH-CH-S(=O)-CH, where up to two heteroatoms may be consecutive, e.g., -CH-NH-OCH. Unless otherwise defined, "C 1-6 The term "alkoxy" refers to an alkyl group containing 1 to 6 carbon atoms attached to the remainder of the molecule through an oxygen atom. 1-6 Alkoxy is C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4 and C3 alkoxy, etc. 1-6 Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy and t-butoxy), pentyloxy (including n-pentyloxy, isopentyloxy and neopentyloxy), hexyloxy, and the like.

[0044] Unless otherwise defined, "C 1-3 The term "alkoxy" refers to an alkyl group containing 1 to 3 carbon atoms attached to the remainder of the molecule through an oxygen atom. 1-3 Alkoxy is C 1-3 , C 1-2 , C 2-3, C1, C2 and C3 alkoxy, etc. 1-3 Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.

[0045] Unless otherwise defined, "C 1-6 The term "alkylamino" refers to an alkyl group containing 1 to 6 carbon atoms attached to the remainder of the molecule through an amino group. 1-6 Alkylamino is C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4, C3 and C2 alkylamino, etc. 1-6 Examples of alkylamino include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -N(CH2CH3)(CH2CH3), -NHCH2CH2CH3, -NHCH2(CH3)2, -NHCH2CH2CH2CH3, and the like.

[0046] Unless otherwise defined, "C 1-3 The term "alkylamino" refers to an alkyl group containing 1 to 3 carbon atoms attached to the remainder of the molecule through an amino. 1-3 Alkylamino is C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkylamino, etc. 1-3 Examples of alkylamino include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH2(CH3)2, and the like.

[0047] Unless otherwise defined, "C 1-6 The term "alkylthio" refers to an alkyl group containing 1 to 6 carbon atoms attached to the remainder of the molecule through a sulfur atom. 1-6 Alkylthio is C 1-4 , C 1-3 , C 1-2 , C2-6 , C 2-4 , C6, C5, C4, C3 and C2 alkylthio. 1-6 Examples of alkylthio include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH2(CH3)2, and the like.

[0048] Unless otherwise defined, the term "C 1-3 "Alkylthio" refers to an alkyl group containing 1 to 3 carbon atoms connected to the remainder of the molecule through a sulfur atom. 1-3 Alkylthio is C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkylthio, etc. 1-3 Examples of alkylthio include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH2(CH3)2, and the like.

[0049] Unless otherwise defined, the term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms (either at the specified endpoints or between any two endpoints, e.g., 3, 4, 5, 6 ring atoms, 4 to 11 ring atoms, 6 to 12 ring atoms, etc.), more preferably 3 to 8 carbon atoms, and most preferably 3 to 6 (e.g., 3, 4, 5, or 6) carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc., preferably cycloalkyl, and polycyclic cycloalkyls include spirocycloalkyls, fused cycloalkyls, and bridged cycloalkyls.

[0050] Unless otherwise defined, "C 3-6 "Cycloalkyl" refers to a saturated cyclic hydrocarbon group of 3 to 6 carbon atoms, including monocyclic and bicyclic ring systems, 3-6 Cycloalkyl is C 3-5 , C4-5 and C 5-6 C includes cycloalkyl, and may be monovalent, divalent or polyvalent. 3-6 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0051] The term "heterocyclyl" refers to a heterocyclic group containing 3 to 20 ring atoms, one or more of which is nitrogen, oxygen, or S(O). m (m is an integer of 0 to 2), but does not include a ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms (which may be a specific end point or the interval between any two end points, for example, 3, 4, 5, or 6 ring atoms, 4 to 11 ring atoms, 6 to 12 ring atoms, etc.), of which 1 to 4 are heteroatoms, preferably contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms, and more preferably contains 3 to 6 ring atoms, of which 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclyls include azetidinyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like, preferably tetrahydropyranyl, piperidinyl, pyrrolidinyl. Polycyclic heterocyclyls include spiroheterocyclyl, fused heterocyclyl, and bridged heterocyclyl.

[0052] Unless otherwise defined, the term "3- to 6-membered heterocyclyl," by itself or in combination with other terms, refers to a saturated cyclic group composed of 3 to 6 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from O, S, and N heteroatoms, and the remainder are carbon atoms, in which the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)). p, p is 1 or 2.) This includes monocyclic and bicyclic ring systems, where bicyclic ring systems include spiro rings, fused rings and bridged rings. Additionally, for "3- to 6-membered heterocyclyl", a heteroatom can occupy the position at which the heterocyclyl is attached to the remainder of the molecule. Said 3- to 6-membered heterocyclyl includes 4- to 6-membered, 5- to 6-membered, 4-membered, 5-membered and 6-membered heterocyclyl, etc. Examples of 3- to 6-membered heterocyclyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl, and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl, or homopiperidinyl.

[0053] The term "aryl" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated pi-electron system of 6 to 20 members, preferably 6 to 10 members, more preferably 6 members, such as phenyl and naphthyl. The aryl includes the above aryls fused to a heteroaryl, heterocyclyl, or cycloalkyl ring, where the ring attached to the parent structure is an aryl ring, non-limiting examples of which are: [ka] etc.

[0054] Aryl may be substituted or unsubstituted, and when substituted, the substituents are preferably substituted with one or more substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0055] The term "heteroaryl" refers to a heteroaromatic system containing 1-4 heteroatoms and 5-20 ring atoms, the heteroatoms being selected from oxygen, sulfur and nitrogen. Heteroaryl is preferably 5-10 membered and contains 1-3 heteroatoms, more preferably 5 or 6 membered and contains 1-3 heteroatoms, non-limiting examples include pyrazolyl, imidazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazolyl, pyrazinyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, where the ring attached to the parent structure is a heteroaryl ring, non-limiting examples of which are: [ka] Includes.

[0056] Heteroaryl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably substituted with one or more substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio. Unless otherwise defined, the terms "5- to 6-membered heteroaromatic ring" and "5- to 6-membered heteroaryl" of the present invention may be used interchangeably, and the term "5- to 6-membered heteroaryl" refers to a monocyclic group having a conjugated π-electron system consisting of 5 to 6 ring atoms, of which 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O)). p and p is 1 or 2. The 5-6 membered heteroaryl can be attached to the remainder of the molecule via a heteroatom or a carbon atom. The 5-6 membered heteroaryl includes 5-membered and 6-membered heteroaryl. Examples of 5-6 membered heteroaryl include pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl, and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl, and 5-oxazolyl, etc.), triazolyl (including 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, and 4H-1,2,4-triazolyl, etc.), and the like. aryl and the like), tetrazolyl, isoxazolyl (including 3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl and the like), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl and the like), furanyl (including 2-furanyl and 3-furanyl and the like), thienyl (including 2-thienyl and 3-thienyl and the like), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl and the like), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl and the like).

[0057] Unless otherwise defined, C n-n+m Or C n -C n+m includes any one of the specific cases of n to n+m carbons, for example, C 1-12 are C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 and C12 Including any range of n to n+m, for example, C 1-12 is C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 and C 9-12 Similarly, n-membered to n+m-membered rings indicate that the number of atoms on the ring is n to n+m, and for example, a 3- to 12-membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, and a 12-membered ring, and also includes any range of n to n+m, and for example, a 3- to 12-membered ring includes a 3- to 6-membered ring, a 3- to 9-membered ring, a 5- to 6-membered ring, a 5- to 7-membered ring, a 5- to 10-membered ring, a 6- to 7-membered ring, a 6- to 8-membered ring, a 6- to 9-membered ring, and a 6- to 10-membered ring.

[0058] The term "leaving group" refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (e.g., an affinity substitution reaction). For example, representative leaving groups include trifluoromethanesulfonate; chlorine, bromine, iodine; sulfonate esters such as methanesulfonate, toluenesulfonate, p-bromobenzenesulfonate, p-toluenesulfonate, and the like; acyloxy such as acetoxy, trifluoroacetoxy, and the like.

[0059] The term "protecting group" includes, but is not limited to, "amino protecting group", "hydroxy protecting group" or "mercapto protecting group". The term "amino protecting group" refers to a protecting group suitable for preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to, formyl; acyl such as alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl such as benzyl (Bn), trityl (Tr), 1,1-bis(4'-methoxyphenyl)methyl; silyl such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like. The term "hydroxy protecting group" refers to a protecting group suitable for preventing side reactions of hydroxy. Representative hydroxy protecting groups include, but are not limited to, alkyl, such as methyl, ethyl, and tert-butyl; acyl, such as alkanoyl (e.g., acetyl); arylmethyl, such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), and diphenylmethyl (DPM); silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like.

[0060] The compounds of the present invention can be prepared by a variety of synthetic methods familiar to those skilled in the art, including the specific embodiments listed below, embodiments in combination with other chemical synthetic methods, and equivalent alternative methods familiar to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present invention.

[0061] Compounds were named according to art-conventional names or ChemDraw® software; for commercially available compounds, manufacturer's catalog names were used. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0062] The present application will be specifically described below by examples, but is not intended to limit the present invention in any way. The present application has been described in detail herein, and specific embodiments thereof have been disclosed, and it is obvious to those skilled in the art that various changes and modifications can be made in the specific embodiments of the present application without departing from the spirit and scope of the present application.

[0063] All raw materials used in the present invention are commercially available unless otherwise specified. Experimental materials and reagents used in the following examples are commercially available unless otherwise specified. The present invention uses the following abbreviations: 9-BBN stands for 9-borabicyclo(3.3.1)nonane; Boc2O stands for di-tert-butyl dicarbonate; B2Pin2 stands for bis(pinacolato)diboron; DCM stands for dichloromethane; DMAP stands for 4-dimethylaminopyridine; DMF stands for N,N-dimethylformamide; DIEA stands for N,N-diisopropylethylamine; DMP stands for Dess-Martin reagent; HATU stands for 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; HBF4PCy3 stands for tricyclohexylphosphine tetrafluoroborate; LDA represents lithium diisopropylamide; NaClO2 represents sodium chlorite; NFSI represents N-fluorobenzenesulfonimide; NMM represents N-methylmorpholine; PhI(OAc)2 represents iodosobenzene diacetate; Pd(OAc)2 represents palladium acetate; Pd(dppf)Cl2 represents [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II); THF represents tetrahydrofuran; and Ti(OEt)4 represents ethyl titanate.

[0064] Example 1: Synthesis of Compound 1 [ka] [ka]

[0065] Step 1: Preparation of Compound 1B Compound 1A (20 g, 86.96 mmol) was dissolved in DMF (200 mL), (diacetoxyiodo)benzene (28 g, 86.96 mmol), I2 (22 g, 86.96 mmol), and Pd(OAc)2 (970 mg, 4.35 mmol) were added, and the mixture was reacted at 100 °C for 16 hours. The solvent was spin-dried, ethyl acetate was added, and NaHSO3 solution was added and stirred, and the color changed from black to yellow. It was extracted twice with ethyl acetate, dried, filtered, spun dry under reduced pressure, and separated by column chromatography (9 / 1 pentane / ethyl acetate) to obtain compound 1B (22.4 g, 72%). 1 H NMR (400 MHz, DMSO-d6) δ 13.79 (s, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 3.80 (s, 3H).

[0066] Step 2: Preparation of compound 1C Under the protection of argon gas, compound 1B (13.8 g, 38.76 mmol) was dissolved in tert-butanol (20 mL), DMAP (470 mg, 3.87 mmol) and Boc2O (50 mL, 193.8 mmol) were added, and the mixture was stirred at 80° C. for 2 hours. The mixture was spin-dried under reduced pressure, and separated by column chromatography (9 / 1 pentane / ethyl acetate) to obtain compound 1C (31.4 g, 87%). 1 H NMR (400 MHz, DMSO-d6) δ 7.56 (d, J = 8.4 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 3.81 (s, 3H), 1.57 (s, 9H).

[0067] Step 3: Preparation of compound 1D Compound 1C (6 g, 14.5 mmol, 1 eq) was dissolved in toluene (50 mL), KSAc (6 g, 52 mmol, 3 eq), o-phenanthroline (0.3 eq), and CuI (0.3 eq) were added, and the mixture was protected with N2 and reacted at 100° C. for 2 days. The mixture was spin-dried under reduced pressure and separated by column chromatography (9 / 1 pentane / ethyl acetate) to give compound 1D (3.7 g, 54%). 1 H NMR (400 MHz, DMSO-d6) δ 7.82 (d, J = 8.4 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 3.83 (s, 3H), 2.51 (q, J = 1.9 Hz, 3H), 1.52 (s, 9H).

[0068] Step 4: Preparation of Compound 1E Compound 1D (2.2 g, 6.11 mmol) was dissolved in methanol (30 mL), cesium carbonate (3.0 g, 9.17 mmol) was added, and the mixture was reacted at room temperature for 10 minutes under argon gas protection. The substrate methyl iodide (4.3 g, 30.56 mmol) was further added, and the mixture was stirred at 40°C for 2 hours. The inorganic salts were filtered with diatomaceous earth, spin-dried under reduced pressure, and separated by column chromatography (9 / 1 pentane / ethyl acetate) to obtain compound 1E (5.5 g, 85%). MS (ESI) m / z = 333.1 [M+H] + .

[0069] Step 5: Preparation of compound 1F Compound 1E (5.5 g, 16.5 mmol) was dissolved in DCM (30 mL) and, under the protection of nitrogen gas, boron tribromide (50 mL, 50 mmol, 1 M dichloromethane solution) was added dropwise at -78°C and stirred at room temperature for 60 min. It was quenched with deionized water (50 mL), DCM was removed by spinning under reduced pressure, and the aqueous phase was extracted three times with ethyl acetate. It was dried, filtered, and spun dry under reduced pressure to give compound 1F (2.6 g, 60%). MS (ESI) m / z = 263.0 [M+H] + .

[0070] Step 6: Preparation of Compound 1G At room temperature, compound 1F (2.6 g, 10.0 mmol) was added to trifluoroacetic acid (150 mL), and at 80 ° C, acetone (3.5 g, 60 mmol, 44.1 mL) and trifluoroacetic anhydride (6.5 g, 31.2 mmol, 44.1 mL) were simultaneously injected by syringe pump, respectively, and the flow rate was 0.0306 mL / min. After the injection was completed, the reaction solution was concentrated, diluted with ethyl acetate, washed with saturated aqueous sodium bicarbonate solution, washed with water, dried and concentrated the organic phase, and the sample was loaded by dry method, and compound 1G (1.3 g, 43%) was obtained by silica gel column chromatography (9 / 1 petroleum ether / ethyl acetate). MS (ESI) m / z = 305.1 [M + H] + .

[0071] Step 7: Preparation of Compound 1H At room temperature, compound 1G (1.0 g, 3.30 mmol), acrylic acid (713 mg, 9.90 mmol), tetrakis(triphenylphosphine)palladium (381 mg, 0.33 mmol), and triethylamine (1.66 g, 16.5 mmol) were added to dry DMF (30 mL), and the mixture was stirred at 120 °C for about 6 hours under the protection of argon gas. The reaction solution was filtered through diatomaceous earth, the filtrate was concentrated, and the sample was loaded by the dry method, and compound 1H (0.5 g, 52%) was obtained by silica gel column chromatography (9 / 1 petroleum ether / ethyl acetate). MS (ESI) m / z = 295.2 [M+H] + .

[0072] Step 8: Preparation of Compound 1I At 0°C, Br2 (0.92 g, 5.75 mmol) was added dropwise to a solution of compound 1H (1.7 g, 5.25 mmol) in chloroform (40 mL) and reacted for 0.5 h. LCMS showed the disappearance of the raw material. The reaction solution was concentrated to give compound 1I (2.6 g, 100%), which was used directly in the next step.

[0073] Step 9: Preparation of Compound 1J At 0°C, Et3N (0.64 g, 6.3 mmol) was added dropwise to a solution of compound 1I (2.6 g, 5.25 mmol) in DMF (30 mL), and the mixture was allowed to warm to room temperature and react for 2 h. Ethyl acetate was added, and the mixture was rinsed three times with 1 M HCl. The organic phase was concentrated and purified, and separated by column chromatography (0-5% ethyl acetate / pentane) to give compound 1J (580 mg, 31%). 1 H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 8.6 Hz, 1H), 7.13 (d, J = 8.1 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 6.50 (d, J = 8.1 Hz, 1H), 2.49 (s, 3H), 1.73 (s, 6H). MS (ESI) m / z = 329.0 [M+H] + .

[0074] Step 10: Preparation of Compound 1K At room temperature, B2pin2 (637mg, 2.5mmol), KOAc (491mg, 5.0mmol) and Pd(PPh3)4 (193mg, 0.17mmol) were added in sequence to a dioxane (8mL) solution of compound 1J (550mg, 1.7mmol), purged with argon gas three times, and reacted in an oil bath at 70°C for 2 hours. The reaction solution was filtered, concentrated and purified, and separated by column chromatography (0-10% ethyl acetate / pentane) to obtain compound 1K (510mg, 81%). 1 H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 8.5 Hz, 1H), 7.29 (d, J = 14.8 Hz, 1H), 6.84 (d, J = 8.6 Hz, 1H), 5.65 (d, J = 14.9 Hz, 1H), 2.48 (s, 3H), 1.72 (s, 6H), 1.28 (s, 12H). MS (ESI) m / z = 377.2 [M+H] + .

[0075] Step 11: Preparation of compound 1L (1S,2S,3R,5S)-(+)-2,3-pinanediol (461 mg, 2.7 mmol) was added to a solution of compound 1K (510 mg, 1.4 mmol) in THF (8 mL), and the mixture was reacted for 2 hours in an oil bath at 60° C. The reaction solution was concentrated and purified, and separated by column chromatography (0-10% ethyl acetate / pentane) to obtain compound 1L (320 mg, 55%). 1 H NMR (400 MHz, CDCl3) δ 7.92 (dd, J = 8.5 Hz, 1H), 7.31 (d, J = 14.9 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 5.69 (d, J = 14.9 Hz, 1H), 4.33 (dd, J = 8.8, 2.0 Hz, 1H), 2.48 (s, 3H), 2.39 - 2.31 (m, 1H), 2.27 - 2.20 (m, 1H), 2.07 (t, J = 5.5 Hz, 1H), 1.95 - 1.92 (m, 1H), 1.88 - 1.83 (m, 1H), 1.73 - 1.71 (m, 6H), 1.41 (s, 3H), 1.30 (s, 3H), 1.17 (d, J = 10.9 Hz, 1H), 0.85 (s, 3H). MS (ESI) m / z = 429.2 [M+H] + .

[0076] Step 12: Preparation of Compound 1M A solution of diazomethane in diethyl ether (50 mL, ~0.8 M) was added to compound 1L (320 mg, 0.75 mmol) and Pd(OAc)2 in THF (4 mL) and reacted at room temperature for 4 hours. The reaction solution was filtered, concentrated and purified by column chromatography (0-10% ethyl acetate / pentane) to give the crude product (250 mg), which was purified by HPLC to give compound 1M (130 mg, 39%). MS (ESI) m / z = 443.2 [M+H] + .

[0077] Step 13: Preparation of Compound 1 NaOH (1mL, 3N aqueous solution) was added to compound 1M (110mg, 0.25mmol) in dioxane (2mL), and the reaction solution was reacted for 2 hours in a 40℃ oil bath. LCMS showed the disappearance of the raw material. The reaction solution was cooled to 0℃, and TES (1mL), TFA (5mL) and isobutylboronic acid (200mg) were added in sequence, and the temperature was slowly raised to room temperature and reacted for 1 hour. The reaction solution was concentrated, alkalized to pH=10 with 3N NaOH aqueous solution, concentrated, and purified by alkaline HPLC to obtain compound 1 (32mg, 52%). 1 H NMR (400 MHz, D2O) δ 7.07 (d, J = 7.8 Hz, 1H), 6.68 (d, J = 7.8 Hz, 1H), 2.33 (s, 3H), 1.77 - 1.72 (m, 1H), 0.80 - 0.75 (m, 1H), 0.28 - 0.25 (m, 1H), 0.22 - 0.16 (m, 1H). MS (ESI) m / z = 232.8 [M+H-18] + .

[0078] Example 2: Synthesis of Compound 2 [ka]

[0079] Step 1: Preparation of compound 2B At room temperature, compound 2A (50.0 g, 262 mmol) was dissolved in dichloromethane (300 mL), then DMAP (3.20 g, 26.2 mmol) was added, followed by slowly adding Boc2O (66.2 mL, 288 mmol). After the addition was completed, the mixture was stirred at room temperature for 2 hours. Saturated NaHCO3 solution and dichloromethane were added to the reaction solution and separated. The organic phase was further washed twice with saturated NaHCO3 solution, then washed once with water, twice with 2M citric acid, and twice with saturated saline. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 2B (73.5 g, 97%), which was directly used in the next reaction. 1H NMR (400 MHz, CDCl3) δ 7.55 (dt, J = 12.1, 6.1 Hz, 1H), 7.00 (dd, J = 8.7, 2.9 Hz, 1H), 6.89 (ddd, J = 8.8, 7.8, 2.9 Hz, 1H), 1.57 (s, 9H).

[0080] Step 2: Preparation of compound 2C At room temperature, compound 2B (73.5 g, 252 mmol) was dissolved in ultra-dry tetrahydrofuran (400 mL), purged with nitrogen gas three times, then cooled to -65 ° C with dry ice and acetone, slowly added LDA solution (132 mL, 264 mmol, 2 M tetrahydrofuran solution), careful not to exceed -60 ° C during the dropping process, stirred at the same temperature for 4 hours after the dropwise addition was completed, slowly warmed to 0 ° C, and saturated ammonium chloride solution (200 mL) was added. Separated, the aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was further washed with saturated brine twice, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 2C (65.0 g, 88%), which was directly used in the next reaction. 1 H NMR (400 MHz, DMSO-d6) δ 7.56 (dd, J = 8.8, 6.4 Hz, 1H), 6.45 (t, J = 9.2 Hz, 1H), 1.51 (d, J = 6.2 Hz, 9H).

[0081] Step 3: Preparation of compound 2D Compound 2C (65.0 g, 223 mmol) was dissolved in dichloromethane (200 mL) at room temperature, then trifluoroacetic acid (100 mL) was added, stirred at room temperature for 2 h, concentrated to remove the solvent, then slurried with more dichloromethane (50 mL), filtered, and the filtered solid was washed twice with small amounts of dichloromethane to give compound 2D (40.0 g, 76%). 1 H NMR (400 MHz, DMSO-d6) δ 7.79 (dd, J = 8.9, 5.7 Hz, 1H), 6.77 (dd, J = 10.4, 8.9 Hz, 1H).

[0082] Step 4: Preparation of compound 2E At room temperature, trifluoroacetic acid (200 mL) was added to compound 2D (40.0 g, 170 mmol), the raw material was not insoluble, and the atmosphere was replaced with nitrogen gas three times. Then, trifluoroacetic anhydride (71.0 mL, 511 mmol) was added by syringe, and the mixture was stirred at room temperature for 10 minutes. Then, acetone (62.6 mL, 851 mmol) was slowly added by syringe, and the temperature was slowly raised to 100 ° C (external temperature, internal temperature ~ 85 ° C), the raw material gradually dissolved, and the solution turned yellow. The mixture was stirred at that temperature for 48 hours. The mixture was cooled to room temperature, concentrated to remove the solvent, and further ethyl acetate (300 mL) and saturated NaHCO3 solution (100 mL) were added, separated, and the aqueous phase was extracted with ethyl acetate three times. The combined organic phase was washed successively with saturated NaHCO3 solution and saturated saline, dried with anhydrous sodium sulfate, filtered, and concentrated to obtain product 2E (37.5 g, 80%). 1 H NMR (400 MHz, CDCl3) δ 7.74 (dd, J = 9.0, 5.3 Hz, 1H), 6.80 (t, J = 9.2 Hz, 1H), 1.79 (s, 6H). MS (ESI) m / z = 275.0 [M+H] + .

[0083] Step 5: Preparation of compound 2F Compound 2E (500 mg, 1.818 mmol), vinylboronic acid pinacol ester (560 mg, 3.636 mmol), palladium acetate (40.8 mg, 0.182 mmol), SPhos (149 mg, 0.364 mmol) and triethylamine (550.8 mg, 5.45 mmol) were added to dioxane (6.0 mL) and reacted at 80 ° C under argon gas protection for 16 hours (detected by LC-MS). The reaction solution was directly concentrated, the sample was loaded by dry method, and compound 2F (400 mg, 63%) was obtained by silica gel column chromatography. MS (ESI) m / z = 349.2 [M + H] + .

[0084] Step 6: Preparation of compound 2G Compound 2F (400 mg, 1.149 mmol) and pinol (782 mg, 4.60 mmol) were added to tetrahydrofuran (20.0 mL) and reacted at 65° C. for 4 hours (detected by LC-MS). The reaction solution was directly concentrated and subjected to silica gel column chromatography to obtain compound 2G (400 mg, 88%). 1 H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 8.8, 5.8 Hz, 1H), 7.47 (d, J = 18.6 Hz, 1H), 6.85 (t, J = 9.2 Hz, 1H), 6.19 (d, J = 18.6 Hz, 1H), 4.39 (dd, J = 8.7, 1.7 Hz, 1H), 2.46 - 2.35 (m, 1H), 2.31 - 2.21 (m, 1H), 2.16 - 2.08 (m, 1H), 2.00 - 1.91 (m, 2H), 1.78 (d, J = 2.9 Hz, 6H), 1.59 (d, J = 8.0 Hz, 1H), 1.45 (d, J = 6.5 Hz, 3H), 1.32 (s, 3H), 0.88 (s, 3H). MS (ESI) m / z = 401.2 [M+H] + .

[0085] Step 7: Preparation of compound 2H Compound 2G (200 mg, 0.500 mmol) was dissolved in dichloromethane (5.00 mL) at room temperature, and then IrPPy3 (33 mg, 0.050 mmol) was added. The atmosphere was replaced with nitrogen gas three times, and the mixture was irradiated with blue light (460-465 nm, 10 w) at room temperature for 4 hours. The reaction solution was directly subjected to column chromatography (0%-10% EA / PE) to obtain compound 2H (120 mg, 60%). 1H NMR (400 MHz, DMSO-d6) δ 7.92-7.83 (m, 1H), 7.23 (d, J = 12.0 Hz, 1H), 7.11-7.01 (m, 1H), 5.73 (d, J = 12.0 Hz, 1H), 4.39-4.33 (m, 1H), 2.35-2.25 (m, 1H), 2.23-2.15 (m, 1H), 1.98-1.92 (m, 1H), 1.90-1.84 (m, 1H), 1.78-1.66 (m, 8H), 1.32 (s, 3H), 1.26 (s, 3H), 0.81 (s, 3H). MS (ESI) m / z = 401.2 [M+H] + .

[0086] Step 8: Preparation of Compound 2I At room temperature, compound 2H (13.1 g, 32.8 mmol) was dissolved in ultra-dry THF (79 mL), then Pd(OAc)2 (368 mg, 1.64 mmol) was added, and the mixture was purged with argon gas three times, cooled to about 0°C, and diazomethane in diethyl ether (200 mL, ~0.6 M) was slowly added with a syringe, the reaction solution changed from yellow to black, bubbles were generated, and the mixture was slowly warmed to room temperature and stirred for 2 hours. The reaction solution was concentrated at room temperature and purified by column chromatography (0-10% EA / PE) to obtain the crude product compound (10.9 g), which was purified by acidic HPLC to obtain compound 2I (4.3 g, 31%). MS (ESI) m / z = 415.0 [M+H] + .

[0087] Step 11: Preparation of compound 2J At room temperature, compound 2I (150 mg, 0.377 mmol) was dissolved in dimethyl sulfoxide (2 mL), cesium carbonate (246 mg, 0.754 mmol) was added, and the mixture was replaced with argon gas three times. 2-propanethiol (86.1 mg, 1.13 mmol) was added to the reaction system and stirred at 60 ° C overnight. The mixture was cooled to room temperature, diluted with ethyl acetate (10 mL), extracted three times with water (3 mL), and the combined organic phase was washed with brine (3 mL) and concentrated to obtain the crude product, which was purified by column chromatography (0-8% EA / PE) to obtain compound 2J (64 mg, 36%). MS (ESI) m / z = 471 .1 [M+H] + .

[0088] Step 12: Preparation of Compound 2 At room temperature, compound 2J (150 mg, 0.377 mmol) was dissolved in 1,4-dioxane (1 mL), 3M aqueous sodium hydroxide solution (1 mL, 0.816 mmol) was added, and the mixture was stirred at room temperature for 3 hours. The reaction of the raw materials was completed by spot plate. Triethoxysilane (0.126 mL, 112 mg, 0.681 mmol), trifluoroacetic acid (0.628 mL) and isobutylboronic acid (27.7 mg, 0.272 mmol) were added to the reaction system in sequence, and the mixture was stirred at room temperature for 30 minutes. The mixture was filtered and concentrated, and the pH of the reaction system was adjusted to 5 with aqueous sodium bicarbonate solution. The crude product was obtained by concentrating the mixture and purifying it by HPLC to obtain compound 2 (12.8 mg, 34%). 1 H NMR (400 MHz, D2O) δ 6.83 (d, J = 7.7 Hz, 1H), 6.54 (d, J = 7.7 Hz, 1H), 3.05 (dt, J = 13.3, 6.5 Hz, 1H), 1.54 (t, J = 6.7 Hz, 1H), 0.92 (d, J = 6.7 Hz, 6H), 0.58 (t, J = 7.3 Hz, 1H), 0.06 (s, 1H), -0.01 (dd, J = 15.9, 9.0 Hz, 1H). MS (ESI) m / z = 279.1 [M+H] + .

[0089] Example 3: Synthesis of Compound 3 [ka]

[0090] Step 1: Preparation of compound 3A Compound 2J (95.0 mg, 0.229 mmol) was dissolved in dichloromethane (2.00 mL) at room temperature, m-chloroperoxybenzoic acid (119 mg, 0.688 mmol) was added, and the mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (10.0 mL), quenched with an appropriate amount of saturated aqueous sodium thiosulfate solution, washed three times with saturated aqueous sodium bicarbonate solution (3.0 mL), washed once with water (3.0 mL), and the combined organic phase was washed with brine (3.0 mL), concentrated to give the crude product, which was purified by column chromatography (8-10% EA / PE) to give compound 3A (35 mg, 30%). MS (ESI) m / z = 503.1 [M+H] + .

[0091] Step 2: Preparation of compound 3 Produced according to the synthesis method of compound 2 in Example 2. Compound 3A (30 mg, 0.0597 mmol) gave product 3 (6.8 mg, 37%). 1 H NMR (400 MHz, D2O) δ 7.37 (dd, J = 8.1, 3.1 Hz, 1H), 7.21 (dd, J = 8.1, 3.5 Hz, 1H), 3.79 - 3.58 (m, 1H), 2.26 - 2.02 (m, 1H), 1.18 (dd, J = 6.6, 3.0 Hz, 6H), 1.17 - 1.08 (m, 1H), 0.50 (d, J = 8.4 Hz, 1H), 0.44 (dd, J = 10.5, 7.3 Hz, 1H). MS (ESI) m / z = 311.1 [M+H] + .

[0092] Example 4: Synthesis of Compound 4 [ka]

[0093] Step 1: Preparation of compound 4B Produced according to the synthesis method of compound 2J in Example 2. Compound 2I (100 mg, 0.241 mmol) and compound 4A (236 mg, 1.61 mmol) gave product 4B (120 mg, 99%). MS (ESI) m / z = 499.1 [M+H] + .

[0094] Step 2: Preparation of compound 4 Produced according to the synthesis method of compound 2 in Example 2. Compound 4B (150 mg, 0.301 mmol) gave product 4 (36.8 mg, 40%). 1 H NMR (400 MHz, D2O+NaOH) δ 6.84 (d, J = 7.8 Hz, 1H), 6.55 (d, J = 7.8 Hz, 1H), 3.71 - 3.64 (m, 2H), 3.56 (ddd, J = 16.4, 9.3, 4.8 Hz, 2H), 3.44 (dd, J = 9.3, 3.8 Hz, 1H), 1.98 (dd, J = 13.2, 7.6 Hz, 1H), 1.69 - 1.49 (m, 2H), 0.58 (t, J = 7.3 Hz, 1H), 0.12 - 0.04 (m, 2H). MS (ESI) m / z = 307.1 [M+H] + .

[0095] Example 5: Synthesis of Compound 5 [ka]

[0096] Step 1: Preparation of compound 5B Produced according to the synthesis method of compound 2J in Example 2. Compound 2I (200 mg, 0.483 mmol) and compound 5A (212 mg, 1.45 mmol) gave product 5B (210 mg, 87%). MS (ESI) m / z = 499.1 [M+H] + .

[0097] Step 2: Preparation of compound 5 Produced according to the synthesis method of compound 2 in Example 2. Compound 5B (190 mg, 0.381 mmol) gave product 5 (91.5 mg, 78%). 1 H NMR (400 MHz, D2O+NaOH) δ 7.08 (d, J = 7.8 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 3.97 - 3.86 (m, 2H), 3.80 (qd, J = 8.3, 4.9 Hz, 2H), 3.69 (dd, J = 9.3, 3.7 Hz, 1H), 2.22 (dd, J = 13.4, 7.4 Hz, 1H), 1.82 (dd, J = 26.8, 4.3 Hz, 2H), 0.82 (dd, J = 12.1, 4.8 Hz, 1H), 0.37 - 0.28 (m, 1H), 0.28 - 0.18 (m, 1H). MS (ESI) m / z = 307.1 [M+H] + .

[0098] Example 6: Synthesis of Compound 6 [ka]

[0099] Step 1: Preparation of compound 6B Produced according to the synthesis method of compound 2J in Example 2. Compound 2I (150 mg, 0.36 mmol) and compound 6A (288 mg, 1.81 mmol) gave product 6B (144 mg, 78%). MS (ESI) m / z = 512.1 [M+H] + .

[0100] Step 2: Preparation of compound 6 Produced according to the synthesis method of compound 2 in Example 2. Compound 6B (144 mg, 0.282 mmol) gave product 6 (8.4 mg, 9%). 1H NMR (400 MHz, D2O) δ 7.15 (d, J = 7.9 Hz, 1H), 6.89 (d, J = 7.7 Hz, 1H), 4.01 (s, 1H), 3.77 (s, 1H), 3.44 (s, 1H), 3.21 (s, 2H), 2.87 (d, J = 14.4 Hz, 3H), 2.48 (s, 1H), 1.95 (s, 2H), 1.01 (s, 1H), 0.41 - 0.27 (m, 2H). MS (ESI) m / z = 320.1 [M+H] + .

[0101] Example 7: Synthesis of Compound 7 [ka]

[0102] Step 1: Preparation of compound 7B Produced according to the synthesis method of compound 2J in Example 2. Compound 2I (200 mg, 0.483 mmol) and compound 7A (514 mg, 2.90 mmol) gave product 7B (180 mg, 65%). MS (ESI) m / z = 471 .1 [M+H] + .

[0103] Step 2: Preparation of compound 7 Produced according to the synthesis method of compound 2 in Example 2. Compound 7B (180 mg, 0.315 mmol) gave product 7 (40 mg, 46%). 1 H NMR (400 MHz, D2O) δ 6.84 (d, J = 7.8 Hz, 1H), 6.55 (d, J = 7.8 Hz, 1H), 2.64 (t, J = 5.9 Hz, 2H), 2.53 (t, J = 6.3 Hz, 2H), 2.44 - 2.41 (m, 2H), 1.54 (td, J = 8.5, 3.5 Hz, 1H), 0.58 (t, J = 7.2 Hz, 1H). MS (ESI) m / z = 280.1 [M+H] + .

[0104] Example 8: Synthesis of Compound 8 [ka]

[0105] Step 1: Preparation of compound 8 At room temperature, compound 7 (40.0 mg, 0.143 mmol) was dissolved in dimethyl sulfoxide (4.0 mL), N,N-diisopropylethylamine (27.8 mg, 0.215 mmol) was added, and the mixture was replaced with argon gas three times. Compound 8A (48.8 mg, 1.57 mmol) was added to the reaction system and stirred at 60 ° C overnight. The mixture was cooled to room temperature, diluted with ethyl acetate (10.0 mL), extracted with water (3.0 mL) three times, and the combined organic phase was washed with brine (3.0 mL) and concentrated to obtain the crude product. A solution of hydrochloric acid in methanol (4 M, 4 mL) was added and stirred at room temperature overnight. Compound 8 (4.2 mg, 9%) was obtained by purification using alkaline HPLC (0.1% NH4OH). 1 H NMR (400 MHz, CD3OD) δ 7.31 (d, J = 7.9 Hz, 1H), 7.08 (d, J = 7.8 Hz, 1H), 3.47 (dd, J = 14.6, 8.4 Hz, 2H), 3.05 (t, J = 6.1 Hz, 2H), 2.19 (t, J = 7.5 Hz, 1H), 1.33 (s, 1H), 1.28 (s, 1H), 0.59 - 0.50 (m, 1H). MS (ESI) m / z = 322 .0 [M+H] + .

[0106] Example 9: Synthesis of Compound 9 [ka]

[0107] Step 1: Preparation of compound 9A At room temperature, compound 7B (24.0 mg, 0.051 mmol) was dissolved in hydrogen chloride in ethyl acetate (4 M, 5.0 mL) and stirred at room temperature for 18 hours, and TLC plate showed the reaction of the raw material was complete. Concentration gave the crude product compound 9A (26.0 mg), which was used directly in the next step. MS (ESI) m / z = 472.4 [M+H] + .

[0108] Step 2: Preparation of compound 9C At room temperature, compound 9A (20 mg, 0.042 mmol) was dissolved in tetrahydrofuran (4.0 mL), sodium bicarbonate (7.0 mg, 0.085 mmol) was added, and the mixture was replaced with argon gas. Compound 9B (21 mg, 0.085 mmol) was added to the reaction system, and the mixture was stirred at 70°C overnight. The mixture was cooled to room temperature, diluted with ethyl acetate (10.0 mL), and extracted three times with water (3.0 mL). The combined organic phase was washed with brine (3.0 mL) and concentrated to obtain a crude product. Compound 9C (18 mg, 79%) was obtained by separation and purification using column chromatography (MeOH / DCM=1 / 9). MS (ESI) m / z = 540 .0 [M+H] + .

[0109] Step 3: Preparation of compound 9 Produced according to the synthesis method of compound 2 in Example 2. Compound 9 (1.8 mg, 15%) was obtained from compound 7B (18 mg, 0.033 mmol). 1 H NMR (400 MHz, D2O) δ 7.18 (d, J = 7.8 Hz, 1H), 6.87 (d, J = 7.8 Hz, 1H), 3.59 (s, 4H), 3.40 (t, J = 5.7 Hz, 2H), 3.05 (t, J = 5.6 Hz, 2H), 1.86 (t, J = 6.6 Hz, 1H), 0.90 (t, J = 7.9 Hz, 1H), 0.47 - 0.25 (m, 2H). MS (ESI) m / z = 348.0 [M+H] + .

[0110] Example 10: Synthesis of Compound 10 [ka]

[0111] Step 1: Preparation of Compound 10B Aqueous ammonia (20 mL) was added to a sealed canister containing 10A (4.0 g, 46.5 mmol) at room temperature, purged with argon gas for 1 min, swirl and stirred at 110 °C for 14 h, TLC (PE:EA=5:1) showed disappearance of the starting material, concentrated to give racemic compound 10B (4.8 g, 100%). The crude product was used directly in the next reaction without purification.

[0112] Step 2: Preparation of compound 10C At room temperature, racemic 10B (4.8 g, 46.5 mmol) was dissolved in tetrahydrofuran (50 mL), then Boc2O (12.8 mL, 55.8 mmol), NaOH solution (31 mL, 93 mmol, 3M) were added, and the mixture was stirred at room temperature for 2 h, and TLC (PE / EA=5:1) showed the disappearance of the raw material. Ethyl acetate and saturated saline were added to the reaction solution, separated, the aqueous phase was extracted twice with ethyl acetate, and the combined organic phase was further washed three times with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to give racemic compound 10C (6.0 g, 64%). The crude product was used directly in the next reaction without purification. 1 H NMR (400 MHz, CDCl3) δ 4.76 (s, 1H), 4.29 (s, 1H), 4.15 - 4.01 (m, 2H), 3.96 (s, 1H), 3.70 (d, J=8.2 Hz, 1H), 3.62 (dd, J=9.3, 2.4 Hz, 1H), 2.66 (s, 1H), 1.45 (s, 9H).

[0113] Step 3: Preparation of compound 10D At room temperature, compound 10C (1.0g, 4.92mmol) was dissolved in dichloromethane (10mL), then triethylamine (0.89mL, 6.40mmol) was added, and the mixture was cooled to 0°C in an ice bath, then MsCl (0.46mL, 5.90mmol) was slowly added dropwise, and after the addition was completed, the mixture was warmed to room temperature and stirred for 2 hours, and saturated saline was added to the reaction solution, separated, and the organic phase was washed with saturated saline twice more, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 10D (1.3g, 94%). The crude product was not purified and was used directly in the next reaction.

[0114] Step 4: Preparation of compound 10E At room temperature, compound 10D (1.3 g, 4.62 mmol) was dissolved in ultra-dry DMF (30 mL), purged with argon gas three times, then potassium thioacetate (792 mg, 6.93 mmol) was added in batches, the reaction solution was yellow, slowly heated to 65 ° C, and stirred for 18 hours, the raw material was almost consumed, the reaction solution turned black, and a large amount of solid was generated. It was cooled to room temperature, water (200 mL) and ethyl acetate (50 mL) were added and separated, the aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was further washed with saturated brine four times, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by column chromatography (0-50% EA / PE) to obtain compound 10E (570 mg, 47%). 1 H NMR (400 MHz, CDCl3) δ 4.75 (s, 1H), 4.50 (s, 1H), 4.20 (dt, J=13.3, 7.4 Hz, 2H), 4.02 (dd, J=9.3, 5.8 Hz, 1H), 3.67 (dd, J=8.8, 6.4 Hz, 1H), 3.64 - 3.55 (m, 1H), 2.36 (s, 3H), 1.51 - 1.39 (m, 9H). MS (ESI) m / z=206.1 [M-56] + .

[0115] Step 5: Preparation of compound 10F It was prepared according to the synthesis method of compound 2J in Example 2. Compound 2I (150 mg, 0.362 mmol) and compound 10E (284 mg, 1.09 mmol) gave crude racemic compound 10F (mixture of 10F_1 and 10F_2, 130 mg). Compound 10F_P1 (isomer 10F_1 or 10F_2, 30 mg, 13.5%) and compound 10F_P2 (isomer 10F_2 or 10F_1, 32 mg, 14.4%) were prepared and separated by alkaline HPLC. Compound 10F_P1: MS (ESI) m / z=636.2 [M+Na] + ;Compound 10F_P2:MS (ESI) m / z=636.2 [M+Na] + .

[0116] Step 6: Preparation of Compound 10 Produced according to the synthesis method of compound 2 in Example 2. Compound 10F_P1 (30 mg, 0.0489 mmol) gave compound 10-P1 (isomer 10_1 or 10_2, 6.9 mg, 44%). 1 H NMR (400 MHz, D2O) δ 7.13 (d, J=7.9 Hz, 1H), 6.95 (d, J=7.9 Hz, 1H), 4.17 (t, J=9.1 Hz, 1H), 4.04 - 3.96 (m, 1H), 3.87 (d, J=3.9 Hz, 2H), 3.82 - 3.72 (m, 1H), 3.60 (t, J=9.0 Hz, 1H), 1.93 (dd, J=8.1, 3.7 Hz, 1H), 1.01 (t, J=7.6 Hz, 1H), 0.40 - 0.29 (m, 1H), 0.29 - 0.16 (m, 1H). MS (ESI) m / z=322.0 [M+H] + .

[0117] Compound 10F_P2 (30 mg, 0.0489 mmol) gave compound 10-P2 (isomer 10_1 or 10_2, 13.6 mg, 87%). 1H NMR (400 MHz, D2O) δ 7.16 (d, J=7.8 Hz, 1H), 6.94 (d, J=7.9 Hz, 1H), 4.23 (d, J=9.2 Hz, 1H), 4.05 (dd, J=14.6, 8.7 Hz, 1H), 4.00 - 3.91 (m, 2H), 3.81 (s, 1H), 3.67 (t, J=9.1 Hz, 1H), 1.87 (dd, J=15.5, 8.0 Hz, 1H), 0.95 (d, J=6.8 Hz, 1H), 0.30 (d, J=4.3 Hz, 2H). MS (ESI) m / z=322.0 [M+H] + .

[0118] Example 11: Synthesis of Compound 11 [ka]

[0119] Step 1: Preparation of compound 11A At room temperature, compound 10C (2.0 g, 9.85 mmol) was dissolved in tetrahydrofuran (20 mL), then p-nitrobenzoic acid (1.8 g, 10.8 mmol) and triphenylphosphine (3.1 g, 11.8 mmol) were added, and the mixture was cooled to 0°C in an ice bath, and then diethyl azodicarboxylate (2.06 g, 11.8 mmol) was slowly added dropwise, and after the addition was completed, the mixture was warmed to room temperature and stirred for 16 hours. Ethyl acetate and water were added to the reaction solution, separated, and the organic phase was washed twice more with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by column chromatography (0-20% EA / PE) to obtain compound 11A (1.00 g, 29%). MS (ESI) m / z=338.0 [M-14] + .

[0120] Step 2: Preparation of compound 11B Compound 11A (1.00 g, 2.84 mmol) was dissolved in methanol (10 mL) at room temperature, and then lithium hydroxide monohydrate (357 mg, 8.51 mmol) dissolved in water (2 mL) was added and stirred at room temperature for 2 hours. TLC (EA / PE=3:7) showed that the raw material was completely reacted. Ethyl acetate and water were added to the reaction solution, separated, and the organic phase was washed twice with saturated aqueous sodium bicarbonate solution, then washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 11B (512 mg, 89%). The crude product was used directly in the next reaction without purification.

[0121] Step 3: Preparation of compound 11C Produced according to the synthesis method of compound 10D in Example 10. Compound 11C (590 mg, 83.2%) was obtained from compound 11B (512 mg, 2.52 mmol). MS (ESI) m / z=181.0 [M-100] + .

[0122] Step 4: Preparation of compound 11D Produced according to the synthesis method of compound 10E in Example 10. Compound 11D (250 mg, 46%) was obtained from compound 11C (590 mg, 2.10 mmol). MS (ESI) m / z=284.0 [M+Na] + .

[0123] Step 5: Preparation of compound 11E It was prepared according to the synthesis method of compound 2J in Example 2. Compound 2I (132 mg, 0.319 mmol) and compound 11D (250 mg, 0.958 mmol) gave racemic compound 11E (mixture of isomers 10E_1 and 10E_2, 120 mg). Compound 11E_P1 (isomer 11E_1 or 11E_2, 50 mg, 26%) and compound 11E_P2 (isomer 11E_2 or 11E_1, 40 mg, 21%) were prepared and separated by alkaline HPLC. Compound 11E_P1: MS (ESI) m / z=636.3 [M+Na] + ;Compound 11E_P2:MS (ESI) m / z=636.3 [M+Na] + .

[0124] Step 6: Preparation of compound 11 Produced according to the synthesis method of compound 2 in Example 2. Compound 11E_P1 (50 mg, 0.0815 mmol) gave product 11-P1 (isomers 11_1 or 11_2, 23.2 mg, 89%). 1 H NMR (400 MHz, D2O) δ 7.23 (d, J=7.8 Hz, 1H), 7.04 (d, J=7.8 Hz, 1H), 4.28 (dd, J=9.8, 6.9 Hz, 1H), 4.08 (dd, J=10.6, 5.5 Hz, 1H), 3.87 (dd, J=10.6, 2.7 Hz, 1H), 3.80 (dt, J=5.6, 2.9 Hz, 1H), 3.75 (dd, J=11.1, 4.6 Hz, 1H), 3.68 (dd, J=9.8, 5.7 Hz, 1H), 2.12 (d, J=3.7 Hz, 1H), 1.18 (t, J=7.5 Hz, 1H), 0.48 (dd, J=16.9, 7.6 Hz, 1H), 0.41 - 0.32 (m, 1H). MS (ESI) m / z=322.0 [M+H] + .

[0125] Compound 11E_P2 (40 mg, 0.0652 mmol) gave product 11-P2 (isomers 11_1 or 11_2, 18.4 mg, 88%). 1H NMR (400 MHz, D2O) δ 7.23 (d, J=7.7 Hz, 1H), 7.04 (d, J=7.9 Hz, 1H), 4.27 (dd, J=9.8, 6.8 Hz, 1H), 4.08 (dd, J=10.6, 5.6 Hz, 1H), 3.87 (dd, J=10.6, 2.8 Hz, 1H), 3.82 - 3.78 (m, 1H), 3.75 (dd, J=11.0, 4.5 Hz, 1H), 3.68 (dd, J=9.8, 5.6 Hz, 1H), 2.10 (t, J=9.9 Hz, 1H), 1.16 (t, J=8.2 Hz, 1H), 0.46 (dd, J=16.2, 8.1 Hz, 1H), 0.40 - 0.31 (m, 1H). MS (ESI) m / z=322.0 [M+H] + .

[0126] Example 12: Synthesis of Compound 12 [ka]

[0127] Step 1: Preparation of compound 12B Produced according to the synthesis method of compound 10C in Example 10. Compound 12B (1.9 g, 96%) was obtained from compound 12A (1.0 g, 9.7 mmol). 1 H NMR (400 MHz, DMSO-d6) δ 7.06 (d, J=6.7 Hz, 1H), 5.15 (d, J=4.0 Hz, 1H), 4.02 (tt, J=4.2, 2.1 Hz, 1H), 3.86 (dd, J=8.8, 5.6 Hz, 1H), 3.81 - 3.76 (m, 1H), 3.72 (s, 1H), 3.45 (dt, J=8.8, 2.3 Hz, 2H), 1.39 (s, 9H).

[0128] Step 2: Preparation of compound 12C Produced according to the synthesis method of compound 10D in Example 10. Compound 12C (688 mg, 100%) was obtained from compound 12B (500 mg, 2.46 mmol). MS (ESI) m / z=181.2 [M-100] + .

[0129] Step 3: Preparation of compound 12D Produced according to the synthesis method of compound 10E in Example 10. Compound 12D (430 mg, 67%) was obtained from compound 12C (688 mg, 2.46 mmol). MS (ESI) m / z=206.2 [M+H-56] + .

[0130] Step 4: Preparation of compound 12E Compound 12D (430 mg, 1.65 mmol) and sodium hydroxide (400 mg, 10.0 mmol) were dissolved in methanol (10 mL), purged with argon gas, reacted at 0 ° C for 0.5 hours, adjusted to pH = 6 by adding 0.5 M dilute hydrochloric acid, extracted twice with ethyl acetate, dried over anhydrous sodium sulfate, concentrated the reaction solution, and separated by column chromatography (PE / EA = 80:20) to obtain compound 12E (320 mg, 59%). MS (ESI) m / z = 164.2 [M + H-56] + .

[0131] Step 5: Preparation of compound 12F Produced according to the synthesis method of compound 2J in Example 2. Compound 12F (100 mg, 58%) was obtained from compound 2I (100 mg, 0.24 mmol) and compound 12E (110 mg, 0.5 mmol). MS (ESI) m / z=514.4 [M+H-100] + .

[0132] Step 6: Preparation of Compound 12G To a solution of compound 12F (100 mg, 0.163 mmol) in tetrahydrofuran (1 mL), hydrogen chloride in dioxane (2 mL) was added and stirred at 0° C. for 2 hours. After completion of the reaction, the mixture was concentrated to give compound 12G (90 mg, 100%). The crude product was used directly in the next reaction without purification. MS (ESI) m / z=514.4 [M+H] + .

[0133] Step 7: Preparation of compound 12H Compound 12G (90 mg, 0.163 mmol), compound 8A (186 mg, 0.6 mmol), and DIPEA (78 mg, 0.6 mmol) were dissolved in acetonitrile (4.0 mL), stirred overnight at room temperature, and separated using a reverse phase column to obtain compound 12H (110 mg, 89%). MS (ESI) m / z=756.6 [M+H] + .

[0134] Step 8: Preparation of Compound 12I Compound 12H (30 mg, 0.047 mmol) and sodium hydroxide (80 mg, 2.0 mmol) were dissolved in tetrahydrofuran / water (0.5 mL / 0.5 mL) and stirred at 30° C. for 3 hours. After the reaction was completed, the mixture was cooled to 0° C. and adjusted to pH=3-4 with trifluoroacetic acid. Then, trifluoroacetic acid (1.0 mL), triethylsilane (0.3 mL), and isobutylboronic acid (51 mg, 0.5 mmol) were added in sequence at 0° C., and stirring was continued for 2 hours at 0° C. After the reaction was completed, the mixture was adjusted to pH=9 with sodium hydroxide at 0° C. Compound 12I (50 mg, 38%) was obtained by alkaline HPLC. MS (ESI) m / z=402.1 [M+H-100] + .

[0135] Step 9: Preparation of Compound 12 Compound 12I (8 mg, 0.018 mmol) was dissolved in tetrahydrofuran (0.1 mL), hydrogen chloride in dioxane (0.3 mL) was added, and the mixture was stirred for 2 hours at 0° C. After completion of the reaction, compound 12 (1.1 mg, 17%) was obtained by purification using alkaline HPLC. 1H NMR (400 MHz, D2O) δ 6.93 (d, J=7.8 Hz, 1H), 6.64 (d, J=7.8 Hz, 1H), 4.10-4.07 (m, 1H), 3.98-3.94 (m, 1H), 3.85-3.81 (m, 2H), 3.67-3.64 (m, 1H), 3.54-3.50 (m, 1H), 1.65-1.62 (m, 1H), 0.69-0.66 (m, 1H), 0.20-0.03 (m, 2H). MS (ESI) m / z=364.0 [M+H] + .

[0136] Example 13: Synthesis of Compound 13 [ka]

[0137] Step 1: Preparation of compound 13B Compound 13A (10.0 g, 142.8 mmol) was dissolved in tert-butanol (50 mL), sodium tert-butoxide (14.4 g, 150 mmol), nitromethane (9.2 g, 150 mmol) were added in batches at 0° C., stirred at 0° C. for 2 hours, diluted with ethyl acetate (500 mL), filtered the cloudy solution, washed the mother liquor with 1M aqueous HCl, washed the organic phase once with saturated NaCl solution, dried over anhydrous sodium sulfate, and concentrated to give compound 13B (18.7 g, 100%). The crude product was used directly in the next reaction without purification. MS (ESI) m / z=114.1[M+H-18] + .

[0138] Step 2: Preparation of compound 13C Compound 13B (18.1 g, 142.8 mmol) and Pd / C (1.0 g) were dissolved in methanol (300 mL), purged with hydrogen gas, and stirred at room temperature overnight. The mixture was filtered through diatomaceous earth and directly concentrated to give compound 13C (14.4 g, 100%). MS (ESI) m / z=102.4 [M+H] + .

[0139] Step 3: Preparation of compound 13D Produced according to the synthesis method of compound 10C in Example 10. Compound 13C (14.4 g, 142.8 mmol) gave compound 13D (13.2 g, 46%). MS (ESI) m / z=202.6 [M+H] + .

[0140] Step 4: Preparation of compound 13E Produced according to the synthesis method of compound 10D in Example 10. Compound 13E (11.0 g, 70%) was obtained from compound 13D (10.0 g, 49.5 mmol). MS (ESI) m / z=180.2 [M+H-100] + .

[0141] Step 5: Preparation of compound 13F Produced according to the synthesis method of compound 10E in Example 10. Compound 13F (6.8 g, 66%) was obtained from compound 13E (11.0 g, 39.6 mmol). MS (ESI) m / z=160.2 [M+H-100] + .

[0142] Step 6: Preparation of Compound 13G Produced according to the synthesis method of compound 12E in Example 12. Compound 13G (200 mg, 24%) was obtained from compound 13F (1.0 g, 3.86 mmol). MS (ESI) m / z=218.2 [M+H] + .

[0143] Step 7: Preparation of compound 13H Produced according to the synthesis method of compound 2J in Example 2. Compound 13H (30 mg, 32%) was obtained from compound 2I (60 mg, 0.145 mmol) and compound 13G (110 mg, 0.5 mmol). MS (ESI) m / z=512.0 [M+H-100] + .

[0144] Step 8: Preparation of compound 13I Produced according to the synthesis method of compound 12I in Example 12. Compound 13I (8 mg, 38%) was obtained from compound 13H (30 mg, 0.047 mmol). MS (ESI) m / z=320.2 [M+H-100] + .

[0145] Step 10: Preparation of Compound 13 Produced according to the synthesis method of compound 12 in Example 12. Compound 13 (0.7 mg, 9%) was obtained from compound 13I (10 mg, 0.0238 mmol). 1 H NMR (400 MHz, D2O) δ 7.57 (d, J=8.0 Hz, 1H), 6.70 (d, J=8.0 Hz, 1H), 2.75 - 2.50 (m, 2H), 2.35 - 2.25 (m, 1H), 1.25 - 1.75 (m, 1H), 0.70 - 0.60 (m, 2H), 0.60 - 0.40 (m, 2H), 0.30 - 0.20 (m, 4H). MS (ESI) m / z=320.0 [M+H] + .

[0146] Example 14: Synthesis of Compound 14 [ka]

[0147] Step 1: Preparation of compound 14B Produced according to the synthesis method of compound 13B in Example 13. Compound 14B (16.1 g, 100%) was obtained from compound 14A (10.0 g, 100 mmol). MS (ESI) m / z=161.60 [M+H] + .

[0148] Step 2: Preparation of compound 14C Produced according to the synthesis method of compound 13C in Example 13. Compound 14C (13.1 g, 100%) was obtained from compound 14B (16.1 g, 100 mmol). MS (ESI) m / z=131.60 [M+H] + .

[0149] Step 3: Preparation of compound 14D Produced according to the synthesis method of compound 10C in Example 10. Compound 14C (13.1 g, 100 mmol) gave compound 14D (15.2 g, 66%). MS (ESI) m / z=231.6 [M+H] + .

[0150] Step 4: Preparation of compound 14E Produced according to the synthesis method of compound 10D in Example 10. Compound 14E (13.5 g, 100%) was obtained from compound 14D (10.0 g, 43.3 mmol). MS (ESI) m / z=210.0 [M+H-100] + .

[0151] Step 5: Preparation of compound 14F Produced according to the synthesis method of compound 10E in Example 10. Compound 14F (8.7 g, 69%) was obtained from compound 14E (13.5 g, 43.7 mmol). MS (ESI) m / z=190.2 [M+H-100] + .

[0152] Step 6: Preparation of compound 14G Produced according to the synthesis method of compound 12E in Example 12. Compound 14G (500 mg, 59%) was obtained from compound 14F (1.0 g, 3.45 mmol). MS (ESI) m / z=248.0 [M+H] + .

[0153] Step 7: Preparation of compound 14H Produced according to the synthesis method of compound 2J in Example 2. Compound 2I (60 mg, 0.145 mmol) and compound 14G (124 mg, 0.5 mmol) gave compound 14H_P1 (isomer 14H_1 or 14H_2, 32 mg, 34%) and compound 14H_P2 (isomer 14H_2 or 14H_1, 30 mg, 32%). 14H_P1: MS (ESI) m / z=542.0 [M+H-100] + ;14H_P2:MS (ESI) m / z=542.0 [M+H-100] + .

[0154] Step 8: Preparation of compound 14I Produced according to the synthesis method of compound 12I in Example 12. Compound 14H_P1 (32 mg, 0.05 mmol) gave compound 14I_1 (isomer 14I_1 or 14I_2, 9 mg, 40%); Compound 14H_P2 (30 mg, 0.05 mmol) gave compound 14I_P2 (isomer 14I_2 or 14I_1, 8 mg, 38%). 14I_P1: MS (ESI) m / z=350.2 [M+H-100] + ;14I_P2:MS (ESI) m / z=350.2 [M+H-100] + .

[0155] Step 10: Preparation of Compound 14 Produced according to the synthesis method of compound 12 in Example 12. Compound 14I_P1 (9 mg, 0.02 mmol) gave compound 14_P1 (isomer 14_1 or 14_2, 5.5 mg, 78%). 1 H NMR (400 MHz, D2O)δ 6.78 (d, J=7.7 Hz, 1H), 6.50 (d, J=7.7 Hz,1H), 3.75 - 3.51 (m, 3H), 3.47 - 3.39 (m, 2H), 3.31 - 3.21 (m, 2H), 2.81 - 2.75 (m, 1H), 2.37 - 2.32 (m, 1H), 2.26 - 2.16 (m, 1H), 1.88 - 1.78 (m, 1H), 1.52 - 1.46 (m, 1H), 0.58 - 0.50 (m, 1H), 0.03 - 0.01 (m, 1H). MS (ESI) m / z=350.2 [M+H] + .

[0156] Compound 14I_P2 (8 mg, 0.018 mmol) gave compound 14_P2 (isomer 14_2 or 14_1, 1.1 mg, 17%). 1H NMR (400 MHz, D2O) δ 6.82 (d, J=7.8 Hz, 1H), 6.54 (d, J=7.5 Hz, 1H), 3.78 - 3.60 (m, 2H), 3.48 - 3.44 (m, 1H), 3.32 - 3.29 (m, 1H), 2.84 - 2.80 (m, 1H), 2.42 - 2.21 (m, 3H), 1.88 - 1.80 (m, 1H), 1.55 - 1.50 (m, 2H), 0.58 - 0.56 (m,1H), 0.10 - 0.07 (m, 2H). MS (ESI) m / z=350.2 [M+H] + .

[0157] Example 15: Synthesis of Compound 15 [ka]

[0158] Step 1: Preparation of compound 15A Compound 2E (5 g, 18.2 mmol) was dissolved in N,N-dimethylformamide (100 mL), and 4-methoxybenzyl mercaptan (4.2 g, 27.3 mmol) and cesium carbonate (17.7 g, 54.6 mmol) were added under nitrogen gas atmosphere, and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was filtered, the cake was washed with ethyl acetate, the filtrate was combined, concentrated under reduced pressure, 50 mL of methanol was added, and the mixture was stirred for 10 minutes, filtered, the cake was washed with methanol, and dried under reduced pressure to obtain white solid 15A (5.7 g, yield: 76.1%). 1 H NMR (400 MHz, DMSO-d6) δ 7.85 (d, J=8.7 Hz, 1H), 7.39 - 7.34 (m, 2H), 7.15 (d, J=8.8 Hz, 1H), 6.95 - 6.88 (m, 2H), 4.20 (s, 2H), 3.74 (s, 3H), 1.69 (s, 6H).

[0159] Step 2: Preparation of compound 15B Compound 15A (3 g, 7.3 mmol) was dissolved in dichloromethane (30 mL), trifluoromethanesulfonic acid (2 mL) was added at 0° C., and stirring was continued for 1 h. After completion of the reaction, sodium bicarbonate solution was added to adjust the pH to neutral, and extracted with dichloromethane (50 mL×3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 3 g of crude product 15B, which was used directly in the next step without purification. MS (ESI) m / z: (M+H)+= 288.80.

[0160] Step 3: Preparation of compound 15C Compound 15B (3 g, 7.3 mmol) was dissolved in N,N-dimethylformamide (30 mL) at room temperature, potassium carbonate (1.5 g, 10.95 mmol) and 2-(4-morpholine)ethyl bromide (2.0 g, 7.3 mmol) were added, and the mixture was stirred for 2 hours. After the reaction was completed, the mixture was washed with water (100 mL), extracted with ethyl acetate (50 mL x 3), and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 5:3) to obtain compound 15C (2.6 g, two-step yield: 88.4%). MS (ESI) m / z: (M+H)+ = 401.8.

[0161] Step 4: Preparation of compound 15D Compound 15C (1.6g, 3.9mmol), acrylic acid (861.8mg, 11.9mmol), palladium acetate (175.1mg, 0.78mmol), tri(o-tolyl)phosphine (948.4mg, 3.1mmol), diisopropylethylenediamine (2.5g, 19.5mmol) were dissolved in N,N-dimethylformamide (20mL), purged with nitrogen gas three times, heated to 100℃, and stirred for 16 hours. After the reaction was completed, it was cooled to room temperature, water (50mL) was added, extracted with ethyl acetate (50mL×3), the organic phase was combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was separated and purified by column chromatography (dichloromethane / methanol=10:1) to obtain compound 15D (1.1g, yield: 70.5%). MS (ESI) m / z (M+ H) +=394.0.

[0162] Step 5: Preparation of compound 15E Compound 15D (676 mg, 1.72 mmol) was dissolved in chloroform (6 mL), and acetic acid (2 mL) was added in an ice bath, followed by slowly adding liquid bromine (330 mg, 2.06 mmol) dropwise, and stirring was continued at 0° C. for 2 hours. After the reaction was completed, it was concentrated under reduced pressure to obtain a residual solid, and N,N-dimethylformamide (6 mL) was added, and triethylamine (347.4 mg, 3.44 mmol) was added at room temperature, and stirring was continued for 1 hour. After the reaction was completed, it was diluted by adding ethyl acetate (20 mL), washed with water (50 mL×3), washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography (petroleum ether / ethyl acetate=5:3) to obtain compound 15E (488 mg, yield: 66.4%). MS (ESI) m / z: (M+H)+= 428.0.

[0163] Step 6: Preparation of compound 15F Compound 15E (1.3 g, 3.04 mmol) was dissolved in isopropyl acetate (10 mL), and bis(1S,2S,3R,5S)(+)-pinene diol diboron ester (1.63 g, 4.56 mmol), allylpalladium(II) chloride dimer (111.0 mg, 0.304 mmol), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (289.8 mg, 0.608 mmol) and potassium isooctanoate (1.2 g, 6.69 mmol) were added. The mixture was replaced with argon gas four times, heated to 35°C, and stirred for 16 hours. After completion of the reaction, it was washed with water (100 mL), extracted with ethyl acetate (50 mL x 3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 5:3) to obtain compound 15F (372 mg, yield: 23.5%). MS (ESI) m / z: (M+H)+ = 528.2.

[0164] Step 7: Preparation of Compounds 15G-a and 15G-b At -20℃ under nitrogen gas atmosphere, compound 15F (97mg, 183.89μmol) and Pd(OAc)2 (4.13mg, 18.39μmol) were dissolved in THF (3mL) and CH2N2 (0.2M, 9.19mL) in diethyl ether was added, and the mixture was allowed to warm to room temperature and stirred for 16 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (0-40% petroleum ether / ethyl acetate) to obtain a mixture of yellow oily compound 15G (60mg, yield: 60.25%), which was separated and purified by SFC to obtain compounds 15G-a and 15G-b.

[0165] SFC separation conditions: Chiral column: Chiralpak IC-3 150×4.6 mm ID, 3 μm; Mobile phase: 50% of IPA (0.05% DEA) in CO2; Flow rate: 2.5 mL / min; Column temperature: 35°C; ABPR: 1500 psi. 15G-a: Retention time: t=4.021min, HPLC: 91.78%; Retention time: t=4.52min, 25mg of white solid. 15G-b: Retention time: t=4.860min, HPLC: 94.11%; Retention time: t=4.58min, 25mg of white solid. MS (ESI) m / z (M+1)+=542.4.

[0166] Step 13: Preparation of compounds 15-a and 15-b A NaOH solution (3M, 46.17uL) was added to a dioxane (1mL) solution containing compound 15G-a (25mg, 46.17μmol) and stirred at room temperature for 24 hours. The reaction solution was then cooled to 0℃, and triethylsilane (0.1mL), trifluoroacetic acid (0.2mL) and isobutylboronic acid (9.41mg, 92.34μmol) were added in sequence and stirred for 1 hour. After completion of the reaction, the mixture was concentrated under reduced pressure, and the crude product was separated and purified by HPLC to obtain 15-a (5mg, yield: 31.01%).

[0167] 1 H NMR (400MHz, METHANOL-d4) δ=7.39 (d, J=8.1 Hz, 1H), 7.24 (d, J=8.0 Hz, 1H), 3.89 (br s, 4H), 3.28 - 3.19 (m, 8H), 2.27 (dt, J=4.2, 7.9 Hz, 1H), 1.42 - 1.32 (m, 1H), 0.66 - 0.58 (m, 1H), 0.41 - 0.33 (m, 1H). MS (ESI) m / z (M+1)+=350.1.

[0168] HPLC separation and purification conditions: Chromatography column: Welch Xtimate C18 100×40mm×3μm; Mobile phase: [water (TFA)-acetonitrile]; B%: 8%~38%, 8min); HPLC 99.92%; retention time: t=1.82min.

[0169] 15-b was produced using 15G-b as the raw material in the same manner as for 15-a to obtain 5 mg. 1H NMR (400MHz, METHANOL-d4) δ=7.39 (d, J=7.9 Hz, 1H), 7.25 (d, J=7.9 Hz, 1H), 3.89 (br s, 4H), 3.27 - 3.17 (m, 8H), 2.28 (dt, J=4.1, 8.1 Hz, MS (ESI) m / z (M+1)+=350.1. HPLC 99.89%; retention time: t=1.69min.

[0170] Example 16: Synthesis of Compound 16 [ka] [ka]

[0171] Step 1: Preparation of compound 16B Liquid bromine (2.05 g, 12.79 mmol) was slowly added to a solution of 16A (1.00 g, 11.62 mmol) and triphenylphosphine (3.35 g, 12.79 mmol) in toluene (10 mL) at -20°C and stirring was continued for 2 h. After completion of the reaction, the mixture was allowed to warm to room temperature, filtered, and washed with toluene (2 mL) to give a solution of 16B in toluene (11 mL, 1.06 N), which was used directly in the next step without purification.

[0172] Step 2: Preparation of compound 16C At room temperature, under nitrogen gas atmosphere, 15B (100 mg, 0.346 mmol) and potassium carbonate (96.0 mg, 0.69 mmol) were dissolved in N,N-dimethylformamide (3 mL) and 16B in toluene (0.4 mL) was slowly added dropwise and stirred at room temperature for 1 hour. After the reaction was completed, water (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (5 mL x 3). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 5:1) to obtain compound 16C (50 mg, yield: 41%). MS (ESI) m / z: (M+H)+ = 357.0.

[0173] Step 3: Preparation of compound 16D A solution of 16C (200 mg, 0.56 mmol), pinacol vinyl boronate (260 mg, 1.68 mmol), tris(dibenzylideneacetone)dipalladium(0) (50.0 mg, 0.056 mmol), tri-tert-butylphosphonium tetrafluoroborate (32.0 mg, 0.11 mmol), and N,N-diisopropylethylamine (215 mg, 1.68 mmol) in toluene (3.0 mL) was stirred at 115 °C for 1 h under nitrogen gas atmosphere. After completion of the reaction, the reaction was quenched by adding water (15 mL) and extracted with ethyl acetate (5 mL × 3). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and directly concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate = 20:1) to obtain compound 16D (140 mg, yield: 58%). MS(ESI) m / z:(M+H)+=431.2.

[0174] Step 4: Preparation of compound 16E At room temperature, (1S,2S,3R,5S)-(+)-2,3-pinanediol (2.00g, 12.2mmol) was added to a solution of compound 16D (1.05g, 2.43mmol) in tetrahydrofuran (12mL) and stirred for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure, and the crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate=10:1) to obtain compound 16E (1.00g, yield: 85.4%). MS (ESI) m / z (M-H) +=483.2.

[0175] Step 5: Preparation of compound 16F Compound 16E (80.0 mg, 0.166 mmol) was dissolved in acetonitrile (8 mL), tris(2-phenylpyridinato)iridium (8.00 mg) was added at room temperature, and the mixture was irradiated with LED blue light (wavelength = 450 nM, 10 W) in a nitrogen gas atmosphere for 1.5 hours. The reaction solution was then concentrated under reduced pressure to obtain a crude product, which was then separated and purified by column chromatography (petroleum ether: ethyl acetate = 20:1) to obtain compound 16F (36 mg, yield: 45%). MS (ESI) m / z (M+ H) + =483.2

[0176] Step 7: Preparation of compound 16G-a or 16G-b Compound 16F (400 mg, 829.12 μmol) was preparatively separated chirally to give white solid compound 16G-a (120 mg, yield: 30.00%) with retention time: t=3.700 min. SFC separation conditions: Chiral column: Chiralcel OD-3 150 mm x 4.6 mm ID, 3 μm; Mobile phase: A: CO2, B: isopropanol (0.05% DEA); Gradient: Mobile phase B increased from 5% to 40% within 5 min, then decreased from 40% to 5% within 30 s and held for 1.5 min; Flow rate: 2.5 mL / min; Column temperature: 35 °C; ABPR: 1500 psi; Retention time: t = 3.700 min.

[0177] 16G-b (130mg, yield: 32.50%), white solid, retention time: t=4.046min. SFC separation conditions: Chiral column: Chiralcel OD-3 150 mm x 4.6 mm ID, 3 μm; Mobile phase: A: CO2 B: Isopropanol (0.05% DEA); Gradient: Mobile phase B increased from 5% to 40% within 5 min, then decreased from 40% to 5% within 30 s and held for 1.5 min; Flow rate: 2.5 mL / min; Column temperature: 35 °C; ABPR: 1500 psi; Retention time: t = 4.046 min.

[0178] Step 8: Preparation of compounds 16H-aa, ab, ba, and bb At -20°C, Pd(OAc)2 (55.84mg, 248.74μmol) was added to a tetrahydrofuran (10mL) solution containing compound 16G-a (120mg, 248.74μmol), then CH2N2 (0.2M, 6.22mL) solution was slowly added dropwise and reacted at room temperature for 16 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was first purified by column chromatography (ethyl acetate / petroleum ether=15%) to obtain a crude product, and further chiral separation was performed to obtain compound 16H-aa (45mg, yield: 36.44%), a white solid, and compound 16H-ab (40mg, yield: 32.39%), a white solid.

[0179] 1H NMR (400MHz, CHLOROFORM-d) δ=7.21 (d, J=8.5 Hz, 1H), 6.84 (d, J=8.3 Hz, 1H), 4.00 (br d, J=7.3 Hz, 1H), 2.94 - 2.85 (m, 1H), 2.32 - 2.24 (m, 1H), 2.17 (br dd, J=8.6, 14.4 Hz, 1H), 1.85 - 1.78 (m, 2H), 1.76 (br s, 2H), 1.75 (s, 3H), 1.71 (s, 3H), 1.44 (d, J=6.6 Hz, 3H), 1.18 (d, J=3.9 Hz, 7H), 1.15 - 1.10 (m, 1H), 1.08 - 1.00 (m, 1H), 1.05 (br dd, J=4.8, 13.0 Hz, 1H), 0.73 (s, 3H), 0.65 - 0.59 (m, 2H), 0.55 - 0.47 (m, 2H), 0.43 - 0.32 (m, 2H). MS (ESI) m / z (M+ H)+=497.4.

[0180] 16H-ab (40 mg, yield: 32.39%), white solid. 1H NMR (400MHz, CHLOROFORM-d) δ=7.23 (d, J=8.5 Hz, 1H), 6.82 (d, J=8.5 Hz, 1H), 4.02 (d, J=6.8 Hz, 1H), 2.85 - 2.78 (m, 1H), 2.34 - 2.26 (m, 1H), 2.15 - 2.07 (m, 1H), 2.02 - 1.95 (m, 1H), 1.85 (t, J=5.6 Hz, 1H), 1.73 (d, J=3.5 Hz, 6H), 1.41 (d, J=6.5 Hz, 3H), 1.33 (br s, 1H), 1.29 - 1.23 (m, 2H), 1.19 (s, 3H), 1.15 - 1.10 (m, 1H), 1.08 (s, 3H), 1.04 - 0.99 (m, 1H), 0.72 (s, 3H), 0.63 (br d, J=8.8 Hz, 3H), 0.58 - 0.52 (m, 1H), 0.43 - 0.38 (m, 1H), 0.36 - 0.31 (m, 1H). MS (ESI) m / z (M+ H)+=497.4.

[0181] SFC separation conditions: Chiral column: Chiralpak IC-3 100 mm x 4.6 mm ID, 3 μm; Mobile phase: A:CO2 B:methanol (0.05% DEA); Gradient: Mobile phase B increased from 5% to 40% within 4 min and held for 2.5 min, then mobile phase was held at 5% for 1.5 min; Flow rate: 2.8 mL / min; Column temperature: 35 °C; ABPR: 1500 psi; Retention time: t = 2.873 min.

[0182] HPLC conditions: Mobile phase: 2.75mL / 4L TFA / water (Mobile phase A), 2.5mL / 4L TFA / acetonitrile (Mobile phase B), increasing from 30% to 90% within 6 minutes using Mobile phase B and holding for 2 minutes, Flow rate: 1.2mL / min; Chromatography column: Ultimate C18 3.0×50mm, 3um; Wavelength: UV 220nm, 215nm, 254nm; Column temperature: 40℃; Retention time: t=6.36min. At -20℃, compound 16G-b (120.00 mg, 248.74 μmol) and Pd(OAc)2 (55.84 mg, 248.74 μmol) were added to a solution of tetrahydrofuran (20 mL) and CH2N2 (10.45 mg, 248.74 μmol) and reacted at room temperature for 16 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (ethyl acetate / petroleum ether = 15%) to obtain a crude product, which was further separated by chiral separation to obtain compound 16H-ba (45 mg, yield: 36.44%, retention time: t = 3.711 min.), a white solid, and compound 16H-bb (40 mg, yield: 32.39%, retention time: t = 4.242 min.), a white solid.

[0183] SFC conditions: Chiral column: (S,S) Whelk-01 100×4.6 mm ID, 5.0 μm; Mobile phase: A:CO2 B:Ethanol (0.05% DEA); Gradient: Mobile phase B increased from 5% to 40% within 4.5 min and maintained for 1.5 min; Flow rate: 2.5 mL / min; Column temperature: 40° C.; ABPR: 100 bar;

[0184] HPLC analysis conditions: Mobile phase: 2.75 mL / 4 L TFA / water (mobile phase A) and 2.5 mL / 4 L TFA / acetonitrile (mobile phase B), increasing from 30% to 90% within 6 min using mobile phase B and maintaining for 2 min, flow rate: 1.2 mL / min; Chromatography column: Ultimate C18 3.0 × 50 mm, 3 μm; Wavelength: UV 220 nm, 215 nm, 254 nm; Column temperature: 40 °C.

[0185] Step 9: Preparation of compounds 16-a, b, c, and d At room temperature, a sodium hydroxide solution (3M, 80μL) was added to a mixed solvent of acetonitrile (1mL) and water (0.5mL) in which compound 16H-aa (40mg, 80μmol) was dissolved, and then the mixture was heated to 60℃ and stirred for 2 hours. The reaction system was cooled to room temperature, and isobutylboronic acid (41mg, 0.4mmol) and hydrochloric acid (100uL) were added to the reaction solution, and stirring was continued at room temperature for 30 minutes. After the reaction was completed, the crude product was obtained by concentration under reduced pressure, and the product was separated and purified by HPLC (chromatography column: Boston Green ODS 150×30mm×5μm; mobile phase: [water(HCl)-ACN]; B%: 40%~60%, 10min) to obtain compound 16-a (10mg, yield: 41%).

[0186] 1 H NMR (400 MHz, Methanol-d4) δ 7.12 (d, J=7.9 Hz, 1H), 6.96 (d, J=7.9 Hz, 1H), 2.39 (dq, J=9.5, 6.7 Hz, 1H), 2.11 (td, J=8.0, 4.2 Hz, 1H), 1.19 (ddd, J=11.1, 7.9, 3.6 Hz, 1H), 1.07 (d, J=6.7 Hz, 3H), 0.65 (dddd, J=13.0, 9.6, 8.1, 4.9 Hz, 1H), 0.42 (ddd, J=10.4, 8.1, 6.1 Hz, 1H), 0.35 - 0.25 (m, 2H), 0.18 (dt, J=6.2, 3.9 Hz, 1H), 0.05 -0.06 (m, 2H). MS (ESI) m / z (M+ H) + =304.7.

[0187] 16b was synthesized in the same manner as 16-a using 16H-ab as the starting material, and 17.88 mg was obtained. 1H NMR (400 MHz, Methanol-d4) δ 7.13 (d, J=7.9 Hz, 1H), 6.97 (d, J=7.9 Hz, 1H), 2.40 (dq, J=9.5, 6.7 Hz, 1H), 2.11 (td, J=8.0, 4.1 Hz, 1H), 1.19 (ddd, J=10.4, 7.9, 3.6 Hz, 1H), 1.08 (d, J=6.7 Hz, 3H), 0.71 - 0.61 (m, 1H), 0.42 (ddd, J=10.4, 8.1, 6.2 Hz, 1H), 0.34 - 0.24 (m, 2H), 0.19 (dt, J=6.2, 3.9 Hz, 1H), -0.00 (ddt, J=6.4, 4.9, 2.2 Hz, 2H). MS (ESI) m / z (M+ H) + =304.7.

[0188] 16-c was synthesized in the same manner as 16-a using 16H-ba as the starting material, and 15.4 mg was obtained: 1 H NMR (400 MHz, Methanol-d4) δ 7.12 (d, J=7.9 Hz, 1H), 6.96 (d, J=7.9 Hz, 1H), 2.39 (dq, J=9.5, 6.7 Hz, 1H), 2.11 (td, J=8.0, 4.1 Hz, 1H), 1.22 - 1.17 (m, 1H), 1.07 (d, J=6.7 Hz, 3H), 0.69 - 0.61 (m, 1H), 0.45 - 0.39 (m, 1H), 0.34 - 0.26 (m, 2H), 0.18 (dt, J=6.2, 3.9 Hz, 1H), 0.04 - -0.04 (m, 2H). MS (ESI) m / z (M+H)+=304.7.

[0189] 16-d was synthesized in the same manner as 16-a using 16H-bb as the starting material, and 21.66 mg was obtained: 1H NMR (400 MHz, Methanol-d4) δ 7.13 (d, J=7.9 Hz, 1H), 6.97 (d, J=7.9 Hz, 1H), 2.40 (dq, J=9.5, 6.7 Hz, 1H), 2.11 (td, J=8.0, 4.1 Hz, 1H), 1.20 (ddd, J=10.5, 8.0, 3.6 Hz, 1H), 1.08 (d, J=6.7 Hz, 3H), 0.70 - 0.62 (m, 1H), 0.42 (ddd, J=10.4, 8.1, 6.1 Hz, 1H), 0.34 - 0.26 (m, 2H), 0.19 (dt, J=6.2, 3.9 Hz, 1H), -0.00 (tdd, J=4.9, 2.8, 1.6 Hz, 2H). MS (ESI) m / z (M+ H)+=304.7.

[0190] Example 17: Synthesis of Compound 17 [ka]

[0191] Step 1: Preparation of compound 17B At -10°C, methanesulfonyl chloride (210mg, 1.84mmol) was slowly added dropwise to a dichloromethane (4mL) solution of compound 17A (200mg, 1.54mmol) and triethylamine (233mg, 2.31mmol) and stirred for 1 hour. After the reaction was completed, the mixture was allowed to return to room temperature, washed with water (10mL), extracted with dichloromethane (20mL x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 17B (319mg, yield: 99%).

[0192] Step 2: Preparation of compound 17C At room temperature, compound 15B (70 mg, 0.24 mmol) and potassium carbonate (50.0 mg, 0.36 mmol) were dissolved in N,N dimethylformamide (1.5 mL), and a DMF solution of 17B (60.0 mg, 0.28 mmol) was added dropwise under nitrogen gas atmosphere. After the addition was completed, the mixture was heated to 100 °C and stirred for 1 hour. After the reaction was completed, the mixture was washed with water and extracted with ethyl acetate (5 mL × 3), and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate = 5: 1) to obtain compound 17C (45 mg, yield: 46%). MS (ESI) m / z: (M + H) + = 401.0.

[0193] Step 3: Preparation of compound 17D At room temperature, 17C (40.0 mg, 0.1 mmol), pinacol vinyl boronate (46.0 mg, 0.3 mmol), tris(dibenzylideneacetone)dipalladium(0) (9.15 mg, 0.1 mmol), tri-tert-butylphosphonium tetrafluoroborate (6.0 mg, 0.02 mmol), and N,N-diisopropylethylamine (40 mg, 0.3 mmol) were dissolved in toluene (1.5 mL), purged with nitrogen gas three times, heated to 115 °C, and stirred for 2 hours. After the reaction was completed, the mixture was returned to room temperature, washed with water, and extracted with ethyl acetate (3 mL × 3). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and directly concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate = 10: 1) to obtain compound 17D (26 mg, yield: 55%). MS(ESI) m / z:(M+H)+=475.2.

[0194] Step 4: Preparation of compound 17E At room temperature, (1S,2S,3R,5S)-(+)-2,3-pinanediol (591.0mg, 3.48mmol) was added to a solution of compound 17D (550.0mg, 1.16mmol) in tetrahydrofuran (6mL) and stirred for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether:ethyl acetate=10:1) to obtain compound 17E (520.0mg, yield: 85.2%). MS (ESI) m / z (M-H) +=527.2.

[0195] Step 5: Preparation of compound 17F Compound 17E (100.0 mg, 0.19 mmol) was dissolved in dichloromethane (9 mL), tris(2-phenylpyridine)iridium (5.00 mg) was added at room temperature, and the mixture was irradiated with LED blue light for 1.5 hours in a nitrogen gas atmosphere, then concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain compound 17F (55 mg, yield: 55%). MS (ESI) m / z (M+ H) + =527.2.

[0196] Step 6: Preparation of compound 17G In an ice bath and under nitrogen gas atmosphere, compound 17F (130.0 mg, 0.25 mmol) and palladium acetate (5.50 mg, 0.024 mmol) were dissolved in tetrahydrofuran (6 mL) and diazomethane diethyl ether solution (2.5 mL, 2.5 mmol) was added and stirred for 10 minutes. After the reaction was completed, the mixture was filtered and concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain compound A3-7 (105.0 mg, yield: 79.0%). MS (ESI) m / z (M+ H) + =540.2

[0197] 17G (220 mg, 0.41 mmol) was separated using a chiral preparative column to give four compounds: 17G-a (30.5 mg, retention time t = 8.843), 17G-b (35.2 mg, retention time t = 10.024), 17G-c (26.5 mg, retention time t = 11.146), and 17G-d (36.5 mg, retention time t = 13.983).

[0198] Chiral separation conditions: Chromatography column: Daicel CHIRALPAK® IB 250×30 mm, 10 μm; Mobile phase A: n-hexane; Mobile phase B: ethanol; Detection wavelength: 254 nm; Flow rate: 25 mL / min; Isocratic elution program: Mobile phase A: Mobile phase B=95:05 (V / V).

[0199] Chiral analysis conditions: Chromatography column: Daicel CHIRALPAK® IB 250×4.6 mm, 5 μm: Mobile phase A: n-hexane; Mobile phase B: ethanol; Detection wavelength: 254 nm; Flow rate: 1 mL / min; Column temperature: 30° C.; Time: 20 min; Isocratic elution program: Mobile phase A: Mobile phase B=95:05 (V / V).

[0200] Step 7: Preparation of compounds 17-a, b, c, and d At room temperature, a NaOH solution (3M, 150μL) was added to a mixed solution of acetonitrile (0.6mL) and water (0.2mL) in which compound 17G-a (25mg, 46.3umol) was dissolved, and then the mixture was heated to 60℃ and stirred for 1.5 hours. In an ice bath, triethylsilane (0.2mL), trifluoroacetic acid (1mL) and isobutylboronic acid (9.41mg, 92.34μmol) were added successively to the above mixed solution, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by HPLC to obtain 17-a (10.42mg).

[0201] 1H NMR (400 MHz, Methanol-d4) δ 7.23 (d, J=8.0 Hz, 1H), 7.04 (d, J=8.0 Hz, 1H), 3.98 - 3.72 (m, 2H), 3.33 - 3.23 (m, 2H), 3.11-3.00 (m, 1H), 2.26-2.15 (m, 1H), 1.71 - 1.53 (m, 3H), 1.49 - 1.23 (m, 3H), 1.11 (d, J=6.8 Hz 3H), 0.55-0.45 (m, 1H), 0.31-0.25 (m, 1H). MS (ESI) m / z (M-1)-=347.0.

[0202] HPLC 100.00%(254nM); Retention time: t=2.70min. Separation conditions: Chromatography column: Welch Xtimate® C18 21.2×250 mm; Column temperature: 25° C.; Mobile phase A: water (10.0 mM / L ammonium bicarbonate solution); Mobile phase B: acetonitrile; Gradient: 0-45%, 15 min; Flow rate: 18.0 mL / min, Analytical conditions: Chromatography column: Waters X Bridge 4.6 × 100 mm, 3.5 μm; column temperature: 40 °C; mobile phase A: water (10.0 mM / L ammonium bicarbonate solution); mobile phase B: acetonitrile; gradient: 5% to 95%, 7 min; flow rate 1.0 mL / min. 17-b was produced using 17G-b as the raw material in the same manner as 17-a, yielding 20.46 mg.

[0203] 1H NMR (400MHz, Methanol -d4) δ 7.21 (d, J=8.0 Hz, 1H), 7.00 (d, J=8.0 Hz, 1H), 3.93 - 3.73 (m, 2H), 3.35 - 3.23 (m, 2H), 3.12-3.01 (m, 1H), 2.18-2.07(m, 1H), 1.71-1.55 (m, 3H), 1.46 - 1.17 (m, 3H), 1.11 (d, J=6.8 Hz, 3H), 0.53-0.39 (m, 1H), 0.33-0.24 (m, 1H).

[0204] 17-c was produced using 17G-c as the raw material in the same manner as 17-a, yielding 7.91 mg. 1 H NMR (400 MHz, Methanol-d4) δ 7.23 (d, J=7.9 Hz, 1H), 7.04 (d, J=8.0 Hz, 1H), 3.88 - 3.82 (m, 2H), 3.29 - 3.23 (m, 2H), 3.07 - 3.02 (m, 1H), 2.19 (dt, J=8.0, 4.0 Hz, 1H), 1.62 (tt, J=8.6, 3.2 Hz, 3H), 1.37 (dtd, J=11.0, 3.3, 1.7 Hz, 2H), 1.31 - 1.26 (m, 1H), 1.12 (d, J=6.9 Hz, 3H), 0.50 (ddd, J=10.4, 8.1, 6.1 Hz, 1H), 0.28 (dt, J=6.2, 3.9 Hz, 1H). - =306.8.

[0205] 17-d was produced from 17G-d as the raw material in the same manner as for 17-a, yielding 9.32 mg. 1H NMR (400 MHz, Methanol-d4) δ 7.23 (d, J=7.9 Hz, 1H), 7.04 (d, J=7.8 Hz, 1H), 3.88 - 3.82 (m, 2H), 3.27 (dtd, J=11.9, 5.9, 2.0 Hz, 2H), 3.06 (dd, J=7.0, 5.0 Hz, 1H), 2.19 (td, J=8.0, 4.1 Hz, 1H), 1.67 - 1.58 (m, 3H), 1.43 - 1.33 (m, 2H), 1.31 - 1.25 (m, 1H), 1.12 (d, J=6.9 Hz, 3H), 0.50 (ddd, MS (ESI) m / z (M- H)-=306.8.

[0206] Example 18: Synthesis of Compound 18 [ka] [ka]

[0207] Step 1: Preparation of compound 18B Compound 18A (1.0 g, 8.62 mmol) and dimethylhydroxylamine hydrochloride (930.0 mg, 9.48 mmol, 1.1 equiv) were dissolved in dichloromethane (20.0 mL) solution, N,N'-carbonyldiimidazole (1536.0 mg, 9.48 mmol, 1.1 equiv) was added to the above reaction solution in batches, and stirred at room temperature for 16.0 hours. After the reaction was completed, it was quenched with hydrochloric acid (1.0 N), extracted with ethyl acetate (40 mL x 3), the organic phases were combined, washed with aqueous sodium hydroxide (100.0 mL, 1.0 N), dried, filtered, and concentrated to obtain crude product 18B (1.0 g, yield: 73.0%, colorless liquid), which was used directly in the next step without further purification. 1H NMR (400 MHz, Chloroform-d) δ 4.75 - 4.62 (m, 1H), 3.85 - 3.72 (m, 2H), 3.67 (s, 3H), 3.09 (s, 3H), 2.15 - 2.03 (m, 1H), 1.92 - 1.73 (m, 3H).

[0208] Step 2: Preparation of compound 18C Methylmagnesium bromide (2.3 mL, 3.0 M in THF) was slowly added dropwise to a solution of compound 18B (1.0 g, 6.28 mmol) in tetrahydrofuran (10.0 mL) at 0° C. under argon gas atmosphere, and the mixture was stirred for 1 h at 0° C. After completion of the reaction, the mixture was quenched with saturated aqueous ammonium chloride solution, extracted with ethyl acetate (40 mL×3), dried, filtered, and concentrated under reduced pressure to give crude product 18C (380.0 mg, yield: 53.0%, yellow liquid), which was used directly in the next step without further purification.

[0209] 1 H NMR (400 MHz, Chloroform-d) δ 4.27 - 4.22 (m, 1H), 3.84 - 3.75 (m, 2H), 2.10 (s, 3H), 2.09 - 2.01 (m, 1H), 1.86 - 1.73 (m, 3H).

[0210] Step 3: Preparation of compound 18D Sodium borohydride (253.0 mg, 6.67 mmol, 2.0 equiv) was added in batches to a solution of compound 18C (380.0 mg, 3.33 mmol) in tetrahydrofuran (5.0 mL) at 0° C., slowly warmed to room temperature, and stirred overnight. After completion of the reaction, it was quenched with hydrochloric acid (1.0 N) and extracted with ethyl acetate (10 mL×3). The organic phases were combined, dried, filtered, and concentrated under reduced pressure to give crude product 18D (126.0 mg, yield: 33.0%, yellow liquid), which was used directly in the next step without further purification.

[0211] 1H NMR (400 MHz, Chloroform-d) δ 4.57 - 4.39 (m, 1H), 3.76 - 3.67 (m, 1H), 3.65 - 3.58 (m, 1H), 3.58 - 3.39 (m, 2H), 1.87 - 1.65 (m, 4H), 1.04 - 0.97 (m, 3H).

[0212] Step 4: Preparation of compound 18E Compound 18D (6.0g, 51.72mmol) and triethylamine (14.35mL, 103.44mmol, 2.0equiv) were dissolved in dichloromethane (50.0mL), 4-dimethylaminopyridine (634.0mg, 5.2mmol, 0.1equiv) and p-toluenesulfonyl chloride (19.757g, 103.44mmol, 2.0equiv) were added in sequence, and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (ethyl acetate / petroleum ether=0~10%) to obtain compound 18E (7.0g, yield: 50.1%, colorless liquid). MS (ESI) m / z (M+ H) + =271.

[0213] Step 5: Preparation of compound 18F In an argon gas atmosphere, compound 15B (1.0 g, 3.46 mmol), cesium carbonate (2256.0 mg, 6.92 mmol, 2.0 equiv) dissolved in N,N-dimethylformamide (10.0 mL) was stirred at room temperature for 5.0 min, then 18E (1.4 g, 5.19 mmol, 1.5 equiv) was added and stirred at room temperature for 1. hour. After the reaction was completed, it was quenched with saturated aqueous ammonium chloride solution (100.0 mL), extracted with ethyl acetate (30 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by column chromatography (ethyl acetate / petroleum ether = 0-10%) to obtain compound 18F (1.0 g, yield: 75.0%, yellow liquid). MS (ESI) m / z (M+ H) + =388.8.

[0214] Step 6: Preparation of compound 18G At room temperature, pinacol vinyl boronate (1g, 6.49mmol) was dissolved in tetrahydrofuran (10mL) and (1S,2S,3R,5S)-(+)-2,3-pinanediol (1.3g, 7.79mmol) was added and stirred for 20 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by column chromatography (PE:EA=9:1) to obtain compound 18G (1.3g, yield: 97.15%).

[0215] Step 7: Preparation of compound 18H Compound 18F (1.0g, 2.58mmol), 18G (738mg, 3.1mmol, 1.2equiv), tris(dibenzylideneacetone)dipalladium (473.0mg, 0.517mmol, 0.2equiv), tri-tert-butylphosphonium tetrafluoroborate (297.0mg, 1.03mmol, 0.4equiv) and diisopropylethylamine (0.674mL, 3.87mmol, 1.5equiv) were dissolved in acetonitrile (20.0mL) and purged with argon gas four times, then heated to 100°C and stirred for 1.0 hour. After the reaction was completed, the mixture was filtered and concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0-15%) to obtain compound 18H (1.2g, yield: 90.8%). MS (ESI) m / z (M+ H) + =513.0

[0216] Step 8: Preparation of compound 18I Compound 18H (300.0 mg) was dissolved in dichloromethane (6.0 mL) and tris(2-phenylpyridine)iridium (15.0 mg) was added. The mixture was purged with argon gas four times, and then stirred at room temperature for 2.0 hours under blue light irradiation with a wavelength of 460-465 nm. After the reaction was completed, the crude product was concentrated under reduced pressure, and separated and purified by column chromatography (ethyl acetate / petroleum ether = 0-15%) to obtain compound 18I (175.0 mg, yield: 58%). MS (ESI) m / z (M+ H) += 513.0

[0217] Step 10: Preparation of compounds 18J-a & 18J-b & 18J-c & 18J-d Compound 18I (2.1 g, 4.1 mmol) and palladium acetate (92 mg, 0.41 mmol, 0.1 equiv) were dissolved in tetrahydrofuran (60.0 mL) and a diethyl ether solution of diazomethane (40 mmol) was added and stirred at room temperature for 15 minutes. After the reaction was completed, the residue was concentrated under reduced pressure and separated and purified by column chromatography (ethyl acetate / petroleum ether (v / v) = 0-5%) to obtain the crude product, which was further purified by chiral separation to obtain 18J-a (324.0 mg) and 18J-b (167.0 mg).

[0218] Chiral separation conditions: Chromatography column: Daicel CHIRALPAK® IE250×30 mm, 10 μm; Mobile phase: n-hexane (0.2% DEA)-ethanol (0.2% DEA); Ratio of mobile phase n-hexane and ethanol: 90:10 (V / V); Flow rate: 25.0 mL / min] 18J-c (232.0mg), 18J-d (284.0mg) Chiral separation conditions: Chromatography column: Daicel CHIRALPAK® IE250×30 mm, 10 μm; Mobile phase: [n-hexane (0.2% DEA)-ethanol (0.2% DEA)]; Ratio of mobile phase n-hexane and ethanol: 95:05 (V / V); Flow rate: 25.0 mL / min.

[0219] 18J-a: Retention time: t=25.930min, HPLC:99.72%; 18J-b: Retention time: t=29.544min, HPLC:97.48%; 18J-c: Retention time: t=5.123min, HPLC: 91.2%; 18J-d: Retention time: t=5.650min, HPLC:98.83%; MS (ESI) m / z (M+H) + =527.0

[0220] Step 11: Preparation of compounds 18-a, b, c, and d Compound 18J-a (50.0 mg) was dissolved in acetonitrile (0.5 mL) and sodium hydroxide solution (0.3 mL, 3.0 N) was added, followed by stirring in an oil bath at 65°C for 3.0 hours. After the reaction was completed, the temperature was returned to room temperature, and the pH was adjusted to 1-2 with hydrochloric acid. Isobutylboronic acid (30.0 mg) was then added, and stirring was continued for 10 minutes. After the reaction was completed, the mixture was separated and purified by high-performance preparative liquid chromatography to obtain compound 18-a (16.7 mg).

[0221] HPLC separation conditions: Chromatography column: Welch Xtimate® C18 21.2×250 mm; column temperature: 25° C.; mobile phase: [water (10.0 mM / L formic acid solution)-acetonitrile]; mobile phase to acetonitrile ratio: 40%-45%, 15 min; flow rate: 18.0 mL / min.

[0222] 1 H NMR (400 MHz, DMSO-d6) δ 12.97 (s, 1H), 9.33 (s, 1H), 7.33 (d, J=8.0 Hz, 1H), 7.10 (d, J=7.9 Hz, 1H), 3.84 - 3.70 (m, 2H), 3.61 (dt, J=8.0, 6.6 Hz, 1H), 3.32 - 3.29 (m, 1H), 2.28 (td, J=8.0, 4.0 Hz, 1H), 1.96 - 1.86 (m, 1H), 1.86 - 1.77 (m, 2H), 1.73 - 1.60 (m, 1H), 1.33 (ddd, J=10.9, MS (ESI) m / z (M+ H-18) + =317.0

[0223] Compound 18-b was synthesized using 18J- as the starting material, and the preparation process was similar to that of 18-a to obtain 15.9 mg of 18-b. 1 H NMR (400 MHz, DMSO-d6) δ 12.96 (s, 1H), 9.33 (s, 1H), 7.33 (d, J=7.9 Hz, 1H), 7.11 (d, J=7.9 Hz, 1H), 3.74 (dq, J=14.2, 6.9 Hz, 2H), 3.63 (td, J=7.6, 5.9 Hz, 1H), 3.24 (p, J=6.7 Hz, 2H), 2.28 (td, J=8.0, 4.0 Hz, 1H), 1.93 (dtd, J=11.9, 7.1, 4.9 Hz, 1H), 1.85 - 1.74 (m, 2H), 1.66 - 1.56 (m, 1H), 1.33 (ddd, J=11.0, 7.9, 3.4 Hz, 1H), 1.15 (d, J=6.8 Hz, 3H), 0.54 (ddd, J=10.5, 8.1, 6.1 Hz, 1H), 0.31 (dt, J=6.4, 3.7 Hz, 1H). MS (ESI) m / z (M+ H-18) + =317.0

[0224] Compound 18-c was synthesized by using 18J-c as the starting material and the preparation process was similar to that of 18-a to obtain 15.4 mg of 18-c. 1H NMR (400 MHz, DMSO-d6) δ 12.97 (s, 1H), 9.33 (s, 1H), 7.33 (d, J=8.0 Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 3.80 - 3.69 (m, 2H), 3.63 (td, J=7.7, 5.9 Hz, 1H), 3.25 (t, J=6.7 Hz, 1H), 2.28 (td, J=7.9, 4.0 Hz, 1H), 2.00 - 1.85 (m, 1H), 1.86 - 1.72 (m, 3H), 1.65 - 1.55 (m, 1H), 1.33 (ddd, J=10.9, 7.9, 3.4 Hz, 1H), 1.15 (d, J=6.8 Hz, 3H), 0.53 (ddd, J=10.5, 8.0, 6.1 Hz, 1H), 0.32 (dt, J=6.0, 3.7 Hz, 1H). MS (ESI) m / z (M+ H-18) + =317.0

[0225] Compound 18-b was synthesized from the starting raw materials used in 18J-d, and the manufacturing process was the same as 18-a, and 17.3 mg was obtained from 18-d. 1 H NMR (400 MHz, DMSO-d6) δ 12.97 (s, 1H), 9.33 (s, 1H), 7.33 (d, J=8.0 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 3.88 - 3.69 (m, 2H), 3.61 (dt, J=8.0, 6.6 Hz, 1H), 3.33 (s, 1H), 2.28 (td, J=7.9, 4.0 Hz, 1H), 1.97 - 1.87 (m, 1H), 1.81 (dtt, J=10.1, 7.3, 4.9 Hz, 2H), 1.73 - 1.62 (m, 1H), 1.33 (ddd, MS (ESI) m / z (M+) H-18)+ =317.0

[0226] Example 19: Synthesis of Compound 19 [ka] [ka] [ka]

[0227] Step 1: Preparation of compound 19B At room temperature, compound 19A (5.00 g, 49 mmol), N,O-dimethylhydroxylamine hydrochloride (4.78 g, 49 mmol) were dissolved in dichloromethane (100 mL) and N,N-carbonyldiimidazole (8.74 g, 54 mmol) was added and stirred at room temperature for 16 hours. After the reaction was completed, water (100 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (80 mL x 3). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether: ethyl acetate = 0-100%) to obtain compound 19B (6 g, yield: 84.5%).

[0228] Step 2: Preparation of compound 19C At 0℃ under nitrogen gas atmosphere, methylmagnesium bromide (13.1mL, 1N, 13.1mmol) solution was slowly added dropwise to a solution (20mL) of compound 19B (950mg, 6.55mmol) dissolved in tetrahydrofuran, and the mixture was stirred for 2 hours. After the reaction was completed, the mixture was allowed to return to room temperature, and then water (20mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (30mL×3). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether:ethyl acetate=1:1) to obtain compound 19C (650mg, yield: 90%).

[0229] 1 H NMR (400 MHz, CDCl3-d) δ 4.78 (m, 4H), 3.9 (m, 1H), 2.15 (s, 3H).

[0230] Step 3: Preparation of compound 19D Sodium borohydride (451 mg, 11.88 mmol) was added in batches to a solution of compound 19C dissolved in methanol (15 mL) at 0° C. and stirred for 1 h. After the reaction was completed, water (5 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (dichloromethane:methanol=10:1) to obtain compound 19D (1.1 g, yield: 70.5%). 1 H NMR (400 MHz, DMSO-d6) δ 4.72-4.70 (d, 1H), 4.57-4.54 (m, 2H), 4.45-4.42 (t, 1H), 4.30-4.26 (t, 1H), 3.86-3.78 ((m, 1H), 2.85-2.76 (m, 1H), 0.97-0.95 (d, 3H).

[0231] Step 4: Preparation of compound 19E Compound 19D (750 mg, 7.35 mmol) and triethylamine (1.18 g, 11.76 mmol) were dissolved in dichloromethane (6 mL) and methanesulfonyl chloride (1.09 g, 9.56 mmol) was added in an ice bath and stirred for 2 h. After completion of the reaction, the mixture was quenched by adding water, extracted with ethyl acetate (50 mL x 3), washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give crude product 19E (1.14 g, yield: 86.4%). 1H NMR (400 MHz, DMSO-d6) δ 5.00 (m, 1H). 4.57-4.61 (m, 2H), 4.44-4.47 (t, 1H), 4.36-4.39 (t, 1H), 3.22 (s, 3H),3.24-3.15 ((m, 1H), 1.28-1.26 (d, 3H).

[0232] Step 5: Preparation of compound 19F In a nitrogen gas atmosphere, a solution of compound 19E (1.11 g, 6.2 mmol), 15B (1.78 g, 6.2 mmol), potassium carbonate (1.71 g, 12.4 mmol) and potassium iodide (103 mg, 0.62 mmol) in N,N-dimethylformamide (30 mL) was heated to 90 °C and stirred for 2 hours. After the reaction was completed, it was cooled to room temperature, poured into ice water, extracted with ethyl acetate (150 mL × 3), the organic phase was combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 5:1) to obtain compound 19F (1.67 g, yield: 72.2%). MS (ESI) m / z (M + H) + =375.0

[0233] Step 6: Preparation of compound 19G Compound 19F (1.5 g, 4.03 mmol), pinacol vinyl boronate (3.09 g, 20.2 mmol), tris(dibenzylideneacetone)dipalladium (735 mg, 0.804 mmol), tri-tert-butylphosphonium tetrafluoroborate (465 mg, 1.608 mmol), and diisopropylethylamine (777 mg, 6.06 mmol) were dissolved in acetonitrile (30 mL) and stirred at 90°C for 1 hour under nitrogen gas. After the reaction was completed, the mixture was allowed to warm to room temperature, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 4:3) to obtain compound 19G (1.36 g, yield: 75.9%). MS (ESI) m / z (M+ H) + =447.0

[0234] Step 7: Preparation of compound 19H At room temperature, (1R,2R,3S,5S)-(-)-2,3-pinanediol (2.06g, 12.1mmol) was added to compound 19G (1.35g, 3.03mmol) dissolved in tetrahydrofuran (30mL) and stirred for 16 hours. After completion of the reaction, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified with (petroleum ether / ethyl acetate = 5:1) to obtain compound 19H (900mg, yield: 59.6%). MS (ESI) m / z: (M+H)+ = 499.0

[0235] Step 8: Preparation of compound 19I Compound 19H (900 mg, 1.8 mmol) was dissolved in dichloromethane (7 mL) and tris(diphenylpyridine)iridium (24 mg, 0.36 mmol) was added. The mixture was irradiated with blue light (wavelength: 460-465 nm, 10 W) for 70 minutes in a nitrogen gas atmosphere. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 3:1) to obtain 19I (550 mg, yield: 61%). MS (ESI) m / z: (M+H)+ = 499.0

[0236] Step 9: Preparation of compounds 19J-a, 19J-b, 19J-c, and 19J-d At -20℃ under nitrogen gas atmosphere, compound 19I (500mg, 1mmol) and Pd(OAc)2 (22mg, 0.1mmol) were dissolved in THF (3mL) and diazomethane diethyl ether solution (20mmol) was added and stirred for 16 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (ethyl acetate / petroleum ether = 0-40%) to obtain a mixture of compound 19J- (500mg, yield: 97.6%), a yellow oily substance, which was separated and purified by SFC to obtain four compounds.

[0237] 19J-a, 60mg, yellow solid, retention time: t=8.889min, MS(ESI) m / z:(M+H)+=513.0; 19J-b, 69mg, yellow solid, retention time: t=9.890min, MS(ESI) m / z:(M+H)+=513.0; 19J-c, 71mg, yellow solid, retention time: t=10.979min, MS(ESI) m / z:(M+H)+=513.0; 19J-d, 66mg, yellow solid, retention time: t=12.86min, MS(ESI) m / z:(M+H)+=513.0;

[0238] Chiral separation conditions: Chromatography column: Daicel CHIRALPAK® IB 250×30 mm, 10 μm; Mobile phase A: n-hexane; Mobile phase B: isopropanol; Detection wavelength: 254 nm; Flow rate: 25 mL / min; Isocratic elution procedure: Mobile phase A: Mobile phase B=80:20 (V / V). Chiral analysis conditions: Chromatography column: Daicel CHIRALPAK® IB 250×4.6 mm, 5 μm: Mobile phase A: n-hexane; Mobile phase B: ethanol; Detection wavelength: 254 nm; Flow rate: 1 mL / min; Column temperature: 30° C.; Time: 20 min; Isocratic elution procedure: Mobile phase A: Mobile phase B=80:20 (V / V).

[0239] Step 13: Preparation of compounds 19-a, 19-b, 19-c, and 19-d At room temperature, a sodium hydroxide solution (3M, 330μL) was added to a mixed solvent of acetonitrile (1mL) and water (0.2mL) in which compound 19J-a (40mg, 78.1μmol) was dissolved, and then the mixture was heated to 60℃ and stirred for 3 hours. The reaction system was cooled to room temperature, and triethylsilane (0.2mL), trifluoroacetic acid (1.2mL) and isobutylboronic acid (24mg, 0.234mmol) were added to the reaction solution, and stirring was continued at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by HPLC to obtain compound 19-a (18mg, yield: 72%).

[0240] 1H NMR (400 MHz, Methanol-d4) δ 7.25 (d, J=7.9 Hz, 1H), 7.07 (d, J=7.9 Hz, 1H), 4.63 (dd, J=8.1, 6.2 Hz, 1H), 4.55 (dd, J=7.9, 6.3 Hz, 1H), 4.37 (dt, J=13.1, 6.5 Hz, 2H), 3.45 (dd, J=9.9, 6.7 Hz, 1H), 3.05 - 2.91 (m, 1H), 2.20 (td, J=8.0, 4.1 Hz, 1H), 1.28 (ddd, J=10.3, 8.0, 3.6 Hz, 1H), 1.10 (d, HPLC 100.00%(254nM); Retention time: t=5.379min. MS (ESI) m / z (M-1)-=321.3.

[0241] HPLC separation conditions: Chromatography column: Welch Xtimate® C18 21.2×250 mm; column temperature: 25° C.; mobile phase: [water-acetonitrile]; ratio of mobile phase to acetonitrile: 30%-35%, 15 min; flow rate: 18.0 mL / min.

[0242] Analytical conditions: Chromatography column: Waters X Bridge 4.6×100 mm, 3.5 μm; Column temperature: 40°C; Mobile phase A: Water (10.0 mM / L ammonium bicarbonate solution); Mobile phase B: Acetonitrile; Gradient: 5%-95%, 7 min; Flow rate: 1.0 mL / min.

[0243] Compound 19-b was synthesized using 19J-b as the starting material, and the preparation process was similar to that of 19-a to obtain 22 mg of 19-b. 1H NMR (400 MHz, Methanol-d4) δ 7.26 (d, J=7.9 Hz, 1H), 7.08 (d, J=7.9 Hz, 1H), 4.64 (dd, J=8.1, 6.2 Hz, 1H), 4.56 (dd, J=7.9, 6.3 Hz, 1H), 4.37 (dt, J=13.2, 6.5 Hz, 2H), 3.45 (dd, J=9.9, 6.7 Hz, 1H), 3.05 - 2.94 (m, 1H), 2.21 (td, J=8.0, 4.1 Hz, 1H), 1.30 (ddd, J=10.4, 7.9, 3.6 Hz, 1H), 1.10 (d, J=6.7 Hz, 3H), 0.52 (ddd, J=10.4, 8.1, 6.2 Hz, 1H), 0.29 (dt, J=6.2, 3.8 Hz, 1H). MS (ESI) m / z (M+ H-18) +=321.3

[0244] Compound 19-c was synthesized from the starting raw materials used in 19J-c, and the manufacturing process was the same as 19-a and 12 mg was obtained from 19-c. 1 H NMR (400 MHz, Methanol-d4) δ 7.25 (d, J=7.9 Hz, 1H), 7.08 (d, J=7.9 Hz, 1H), 4.63 (dd, J=8.1, 6.2 Hz, 1H), 4.55 (dd, J=7.9, 6.3 Hz, 1H), 4.36 (dt, J=18.3, 6.4 Hz, 2H), 3.45 (dd, J=9.9, 6.7 Hz, 1H), 2.98 (dddd, J=9.8, 8.0, 6.6, 1.4 Hz, 1H), 2.21 (td, J=8.0, 4.2 Hz, 1H), 1.29 (ddd, J=11.1, 8.0, 3.6 Hz, 1H), 1.10 (d, J=6.7 Hz, 3H), 0.52 (ddd, J=10.4, 8.1, 6.2 Hz, 1H), 0.28 (dt, J=6.2, 3.9 Hz, 1H). MS (ESI) m / z (M+ H-18) +=321.3.

[0245] Compound 19-d was synthesized by using 19J-d as the starting material and the preparation process was similar to that of 19-a to obtain 7 mg of 19-d. 1 H NMR (400 MHz, Methanol-d4) δ 7.24 (d, J=7.9 Hz, 1H), 7.05 (d, J=7.9 Hz, 1H), 4.63 (dd, J=8.1, 6.2 Hz, 1H), 4.55 (dd, J=7.9, 6.3 Hz, 1H), 4.36 (dt, J=17.6, 6.5 Hz, 2H), 3.45 (dd, J=9.9, 6.7 Hz, 1H), 3.01 - 2.91 (m, 1H), 2.18 (td, J=8.0, 4.0 Hz, 1H), 1.26 (ddd, J=11.2, 7.9, 3.5 Hz, 1H), 1.10 (d, MS (ESI) m / z (M+ H-18) +=321.3.

[0246] Example 20: Synthesis of Compound 20 [ka]

[0247] Step 1: Preparation of compound 20B Sodium borohydride (782 mg, 21 mmol) was added to a solution of compound 20A (4 g, 20 mmol) in methanol (500 mL) at 0°C and stirred for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure to remove methanol, potassium hydroxide solution was added, and extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to obtain compound 20B (3.7 g, yield: 91.57%).

[0248] Step 2: Preparation of compound 20C At 0°C, carbon tetrabromide (7.3 g, 22.1 mmol) was added in batches to compound 20B (3.7 g, 18.4 mmol) and triphenylphosphine (5.8 g, 22.1 mmol) dissolved in dichloromethane (50 mL), then the mixture was slowly warmed to room temperature and stirred for 16 h. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 5:1) to obtain 20C (3.3 g, yield: 67.95%).

[0249] Step 3: Preparation of compound 20D Potassium carbonate (5.2 g, 37.5 mmol) was added to a solution of compound 20C (3.3 g, 12.5 mmol) and 15B (3.6 g, 12.5 mmol) dissolved in N,N-dimethylformamide (50 mL), purged with nitrogen gas, heated to 60°C, and stirred for 6 hours. After completion of the reaction, the mixture was diluted with ethyl acetate, filtered, and concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 2:1) to obtain compound 20D (3.9 g, yield: 66.09%). MS (ESI) m / z (M- H) + =472.0

[0250] Step 4: Preparation of compound 20E Compound 20D (870 mg, 1.8 mmol), N,N-diisopropylethylamine (250 mg, 1.9 mmol), tri-tert-butylphosphonium tetrafluoroborate (213 mg, 0.7 mmol), tris(dibenzylideneacetone)dipalladium (337 mg, 0.4 mmol) and pinacol vinyl boronate (1.42 g, 9.2 mmol) were dissolved in acetonitrile (9 mL) and heated to 90° C. under nitrogen gas atmosphere for 1 hour. After completion of the reaction, it was diluted with ethyl acetate, filtered and concentrated under reduced pressure to obtain crude compound 20E (1 g), which was used directly in the next step without purification. MS (ESI) m / z (M- H) + =546.2

[0251] Step 5: Preparation of compound 20F Compound 20E (1.5 g, 2.8 mmol) and (1S,2S,3R,5S)-(+)-2,3-pinanediol (2.3 g, 13.8 mmol) in tetrahydrofuran (20 mL) were stirred at room temperature for 4 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain the crude product of compound 20F, which was purified by C18 reverse phase column (MeCN: 0.2% NH4HCO3 = 5% ~ 95%) to obtain the crude product, which was further separated and purified by normal phase column chromatography (petroleum ether / ethyl acetate = 4:1) to obtain compound 20F (1 g, yield: 60.86%). MS (ESI) m / z (M- H) + =598.2

[0252] Step 6: Preparation of compound 20G Compound 20F (200 mg, 0.33 mmol) and tris(2-phenylpyridine)iridium (11 mg, 0.02 mmol) were dissolved in acetonitrile (6 mL), substituted with nitrogen gas, and stirred at room temperature for 1 hour under 10 W blue light irradiation. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to obtain compound 20G (105 mg, yield: 52.50%). MS (ESI) m / z (M- H) + = 598.2

[0253] Step 7: Preparation of compounds 20H-a, 8b, 8c and 8d Compound 20G (645 mg, 1.1 mmol) and palladium acetate (24 mg, 0.1 mmol) were dissolved in tetrahydrofuran (15 mL) and purged with nitrogen gas. Diazomethane in diethyl ether (7.2 mL, 21.6 mmol) was added at 0°C and stirred at room temperature for 1 hour. After the reaction was completed, the mixture was diluted with dichloromethane, filtered to remove solids, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product (550 mg, yield: 83.32%) was separated and purified by column chromatography (petroleum ether / ethyl acetate = 4.5:1), and further separated by chiral separation to obtain 94 mg of 20H-a; 50 mg of 20H-b; 54 mg of 20H-c; and 112 mg of 20H-d; MS (ESI) m / z (M- H) +=612.2. Holding time: 20H-a:t=10.620min;20H-b:t=9.075min;20H-c:t=10.741min;20H-d:t=14.542min.

[0254] 20H-a, 20H-d Chiral separation conditions: Chromatography column: Daicel CHIRALPAK® IE 250×30 mm, 10 μm; Mobile phase A: n-hexane (0.2% DEA); Mobile phase B: isopropanol (0.2% DEA); Detection wavelength: 254 nm; Flow rate: 25 mL / min; Isocratic elution procedure: Mobile phase A: Mobile phase B = 85:15 (V / V).

[0255] Chiral analysis conditions: Chromatography column: Daicel CHIRALPAK® IE 250×4.6 mm, 5 μm; Mobile phase A: n-hexane (0.2% DEA); Mobile phase B: isopropanol (0.2% DEA); Detection wavelength: 254 nm; Flow rate: 1 mL / min; Isocratic elution procedure: Mobile phase A:Mobile phase B=85:15 (V / V).

[0256] 20H-b, 20H-c chiral separation conditions: Chromatography column: Daicel CHIRALPAK® IC 250×30 mm, 10 μm; Mobile phase A: n-hexane; Mobile phase B: isopropanol; Detection wavelength: 254 nm; Flow rate: 25 mL / min; Isocratic elution procedure: Mobile phase A: Mobile phase B=60:40 (V / V).

[0257] Chiral analysis conditions: Chromatography column: Daicel CHIRALPAK® IE 250×4.6 mm, 5 μm; Mobile phase A: n-hexane (0.2% DEA); Mobile phase B: isopropanol (0.2% DEA); Detection wavelength: 254 nm; Flow rate: 1 mL / min; Isocratic elution procedure: Mobile phase A:Mobile phase B=60:40 (V / V) (V / V).

[0258] Step 8: Preparation of Compounds 20I-a, b, c, and d At 0°C, 2,6-dimethylpyridine (42 mg, 0.39 mmol) and trimethylsilyl trifluoromethanesulfonate (106 mg, 0.59 mmol) were added to a dichloromethane (3 mL) solution containing compound 20H-a (60 mg, 0.1 mmol) and stirred for 2 hours. After completion of the reaction, the mixture was concentrated under reduced pressure to obtain a crude product, which was then separated and purified by column chromatography (DCM:MeOH (0.1% NH3) = 9:1) to obtain compound 20I-a (50 mg, yield: 99.64%).

[0259] Step 9: Preparation of Compounds 20I-a, b, c, and d At room temperature, compound 20I-a (50 mg, 0.1 mmol) was dissolved in dichloromethane (1 mL) and formaldehyde aqueous solution (0.3 mL) was added. After stirring at room temperature for 1 hour, sodium triacetoxyborohydride (41 mg, 0.2 mmol) was added to the above reaction solution and stirring was continued for 1 hour. After the reaction was completed, it was quenched by adding saturated sodium bicarbonate solution, extracted with ethyl acetate (10 mL x 3), the organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by column chromatography (DCM:MeOH (0.1% NH3) = 9:1) to obtain compound 20I-a (33 mg, yield: 64.24%). MS (ESI) m / z (M- H) + =526.0

[0260] Step 10: Preparation of Compounds 20-a, b, c, and d Compound 20I-a (33 mg, 0.06 mmol) was dissolved in acetonitrile (1 mL) and water (0.1 mL) and 3N sodium hydroxide (188 uL, 0.57 mmol) were added in sequence to the reaction system, and the mixture was stirred at 60 ° C for 4 hours. TFA (0.5 mL), triethylsilane (0.1 mL), and isobutylboronic acid (19 mg, 0.19 mmol) were added in sequence to the reaction system, and the mixture was stirred for 1 hour. After the reaction was completed, the pH was adjusted to about 6, and the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by HPLC to obtain a crude product compound (12 mg, yield: 72.6%). 0.5 mL of water was added thereto, and 3M sodium hydroxide (19.8 μL, 0.059 mmol) was further added, and the mixture was stirred at 60 ° C for 1 hour. Purification by C18 reverse phase column (separation conditions: chromatographic column: Redi-GOLD (registered trademark) C18 10 μm 33 × 147 mm; mobile phase: [water-acetonitrile]; flow rate: 30 mL / min) gave compound 20-a (6.59 mg, yield: 26.6%). Retention time: t = 1.798 min. 1 H NMR (400 MHz, Deuterium Oxide) δ 7.10 (d, J=7.6 Hz, 1H), 6.90 (d, J=7.8 Hz, 1H), 4.25 - 4.10 (m, 1H), 4.06 - 3.96 (m, 1H), 3.84 - 3.77 (m, 1H), 3.73 - 3.62 (m, 1H), 3.34 (dt, J=21.6, 7.5 Hz, 1H), 2.97 - 2.84 (m, 1H), 2.74 (d, J=25.9 Hz, 3H), 1.96 (s, 1H), 1.07 (dd, J=15.2, 6.8 Hz, 4H), 0.31 (d, J=26.1 Hz, 2H). MS (ESI) m / z (M- H) + =334.2.

[0261] Using the same method as the synthesis of Example 20-a, Examples 20-b to 34-b were synthesized, as shown in Table 1 below: [Table 1-1]

[0262]

Table 1-2

[0263]

Table 1-3

[0264]

Table 1-4

[0265]

Table 1-5

[0266]

Table 1-6

[0267]

Table 1-7

[0268]

Table 1-8

[0269]

Table 1-9

[0270]

Table 1-10

[0271]

Table 1-11

[0272] [Table 1-12]

[0273] [Table 1-13]

[0274] [Table 1-14]

[0275] [Table 1-15]

[0276] [Table 1-16]

[0277] [Table 1-17]

[0278] Test Example 1: Enzyme activity test Compound stock solutions: Compounds were prepared in 50 mM stock solutions in DMSO. Positive control compound VNRX-5133 was prepared in 50 mM stock solutions in DMSO. Compound stock solutions were aliquoted and stored at -20°C. Preparation and storage of antibiotic substrate stock solution: The antibiotic fluorescent substrate FC5 was synthesized in-house, prepared to a 2 mM stock solution, aliquoted and stored at -20°C.

[0279] Storage of β-lactamases: Each β-lactamase was synthesized by Genscript Biotech Corporation and stored at −80°C after aliquoting to avoid repeated freezing and thawing.

[0280] Preparation of enzyme activation reaction buffer: SBL buffer: PBS pH 7.4, 0.01% (v / v) Triton X-100; MBL buffer: 50 mM HEPES in PBS pH 7.2, 1 μM ZnSO4, 1 μg / mL BSA, 0.01% v / v Triton X-100. The buffer was stored at 4°C.

[0281] Experimental steps: a) The test compound and buffer were removed and allowed to warm to room temperature. b) Each compound was diluted in DMSO and buffer to an initial experimental concentration (Table 2), and then the compounds were diluted 3-fold for a total of 10 concentrations. c) Diluted compounds were added to wells 1-20 of a 384-well black plate in two replicate wells at each concentration, 5 μL per well. 5 μL of DMSO was added to each of wells 21-24. d) Each enzyme was diluted to the experimental concentration (Table 2) in SBL and MBL buffers and finally added at 35 μL / well to a total of 22 wells. 35 μL of buffer was added to wells 23-24, where wells 21-22 were set as the highest test value (Max) and wells 23-24 were set as the lowest test value (Min). e) Quickly centrifuged and incubated at room temperature for 10 minutes. f) The antibiotic substrate FC5 was diluted in buffer to experimental concentrations for each enzyme (Table 2). g) After incubation, the 384-well plate was removed, and 10 μL of FC-5 was added to wells 1 to 24. After quick centrifugation, the plate was immediately transferred to a microplate reader and read. h) Fluorescence intensity at an excitation wavelength of 355 nm / emission wavelength of 460 nm was measured every 3 minutes for a total of 10 times using a microplate reader.

[0282] The experimental concentrations are as shown in Table 2. [Table 2] Initial enzyme reaction velocity V: The background readings without enzyme (Min wells) were subtracted from each fluorescence intensity reading, and a linear regression analysis was performed for each compound concentration group. The slope of the regression analysis was the initial enzyme reaction velocity (V) at each compound concentration.

[0283] Compound dose-effect curves and IC 50 Calculation of IC: The initial rate of the enzyme reaction under the influence of each concentration of compound was fitted by nonlinear regression to obtain the formula IC 50 IC of the compound's half-inhibitory concentration according to = (1-Vi / V0) x 100 (Vi: initial enzyme reaction velocity at each compound concentration, V0: initial enzyme reaction velocity without compound (Max well)) 50 was calculated using the software Graphpad prism 8.

[0284] [Table 3] As shown in Table 3, the compounds of the present invention can effectively inhibit four types of β-lactamase compounds, A, B, C, and D, and have significant advantages in inhibitory activity compared with compound VNRX-5133. The commercially available drug Avibactam has good activity against A and C class serine beta-lactamases (SBLs), but has no inhibitory effect against B class metal zinc ion beta-lactamases (MBLs), and also shows low inhibitory effect against D class serine beta-lactamases.

[0285] Test Example 2: Minimum Inhibitory Concentration (MIC) Test of Compounds Against Bacterial Growth (1) Main reagents and consumables: (2) [Table 4]

[0286] (2) Strain: [Table 5]

[0287] (3) Experimental method Preparation of strains: Test strains were streaked onto Mueller Hinton II Agar plates from glycerol tubes at -80°C. They were placed in a 37°C incubator and cultured for 18-24 hours.

[0288] Media preparation: CAMHB (Mueller Hinton II Broth): 22 g of powder was dissolved in 1 L of pure water and sterilized at 121° C. for 10 minutes before use. Saline: 8.5 g of NaCl was dissolved in 1 L of pure water and sterilized at 121° C. for 30 minutes before use. Preparation of compound and antibiotic mother solution: Compound and antibiotic were dissolved in DMSO or water to 12.8 mg / mL.

[0289] Two-fold gradient dilution of antibiotics: 300 μL of CAMHB medium was added to columns 2-12 of a 96-deep-well plate. To column 1, 24 μL of antibiotic stock solution and 576 μL of CAMHB medium were added and mixed evenly to achieve a concentration of 512 μg / mL. 300 μL of antibiotic solution was transferred from column 1 to column 2 and mixed evenly. This was repeated until columns 11 and 12 were blank controls.

[0290] Dilution of combination compounds: Compounds were diluted 400-fold to 32ug / ml in CAMHB medium. Dispense working solution: Use a pipette to dispense 25 µL of antibiotic into a 96-U bottom plate, then add 25 µL of combination compound to each well. If antibiotic was used alone, add 25 µL of CAMHB medium.

[0291] Preparation of inoculum solution: Five to six single colonies were picked from the plate and suspended in saline. The bacterial suspension was diluted to a concentration of 0.2 (i.e., McFarland turbidity 0.5) using a turbidimeter, with a bacterial concentration of approximately 1–2 × 10 8 The bacterial suspension was diluted 100-fold in CAMHB medium for use.

[0292] Inoculation: Using a pipette, 50 μL of inoculation solution was transferred to the 50 μL compound plate above. Culture: The 96-U bottom plate was placed in a 37°C incubator and cultured for 18 to 20 hours.

[0293] (4)MIC evaluation: After incubation was completed, bacterial growth was visually observed and photographs of the test plates were taken, recorded, and archived. The lowest compound concentration at which bacterial growth was completely inhibited was defined as the minimum inhibitory concentration (MIC).

[0294] [Table 6-1]

[0295] [Table 6-2]

[0296] [Table 6-3]

[0297] [Table 6-4]

[0298] [Table 6-5]

[0299] [Table 6-6]

[0300] [Table 6-7]

[0301] [Table 6-8]

[0302] [Table 6-9]

[0303] As shown in Table 6, the compounds of the present invention can effectively restore the activity of antibiotics cefepime / meropenem / biapenem against carbapenem-resistant Acinetobacter baumannii strains. VNRX5133 + cefepime / meropenem is essentially ineffective against all Acinetobacter baumannii drug-resistant strains (MIC ≧ 32 μg / mL), while the compounds of the present invention + meropenem / biapenem are effective against all drug-resistant strains, and are significantly more advantageous in activity and inhibition spectrum than the VNRX5133 + cefepime combination combination.

Claims

1. A compound represented by formula (I), its optical isomer and a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (where: X is S, S(=O) and S(=O) 2 is selected from L 1 is a single bond, C 1-6 Alkyl and C 1-6 heteroalkyl, wherein C 1-6 Alkyl or C 1-6 The heteroalkyl is optionally substituted by 1, 2 or 3 R; L 2 is a single bond, C 3-6 cycloalkyl and 4- to 9-membered heterocycloalkyl; 3-6 cycloalkyl or 4- to 9-membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R; L 3 is a single bond, C 1-6 Alkyl, C 1-6 heteroalkyl and 4- to 9-membered heterocycloalkyl; 1-6 Alkyl, C 1-6 heteroalkyl or 4- to 9-membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R; R 1 NH 2 , 【Chemistry 2】 , -NR a C(=NH)R b , -NR a C(=NH)NR b1 R b2 , -C(=NH)R b , C 1-6 Alkyl, C 3-6 cycloalkyl, 4- to 8-membered heterocycloalkyl, partially unsaturated 4- to 8-membered heterocycloalkyl, and 5- to 6-membered heteroaryl; 1-6 Alkyl, C 3-6 cycloalkyl, 4- to 8-membered heterocycloalkyl, partially unsaturated 4- to 8-membered heterocycloalkyl or 5- to 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R; R, R a , R b , R b1 , R b2 are each independently H, F, Cl, Br, OH, or NH 2 , C.N., C. 1-6 Alkyl and C 3-6 cycloalkyl, wherein C 1-6 Alkyl or C 3-6 Cycloalkyl is optionally substituted by 1, 2 or 3 R'; R' is independently F, Cl, Br, I, or NH 2 , OH and Me; Said C 1-6 Heteroalkyl, 4- to 9-membered heterocycloalkyl, partially unsaturated 4- to 8-membered heterocycloalkyl or 5- to 6-membered heteroaryl are each independently selected from the group consisting of 1, 2 or 3 of O, NH, S, C(=O), C(=NH), C(=O)O, S(=O), S(=O) 2 and N.

2. The compound represented by formula (I) according to claim 1, its optical isomer, and its pharma- ceutically acceptable salt, which is selected from the compounds represented by formulas (IA) and (IB), their optical isomers, and their pharma- ceutically acceptable salts. 【Chemistry 3】 (where: X, L 1 , L 2 , L 3 and R 1 is as defined in claim 1.

3. Each R is independently selected from R, F, Cl, Br, OH, NH 2 , C.H. 3 , 【Chemistry 4】 wherein said CH 3 , 【Chemistry 5】 is optionally substituted by 1, 2 or 3 R', its optical isomers and pharma- ceutically acceptable salts thereof.

4. R is independently F, Cl, Br, OH, or NH 2 , C.H. 3 , 【Chemistry 6】 The compound according to claim 3, its optical isomers and pharma- ceutically acceptable salts thereof, selected from:

5. L 1 is a single bond, C 1-3 Alkyl, -C 1-3 Alkyl-O-, -C 1-3 Alkyl-S-, -C 1-3 Alkyl-NH- and -C 1-3 alkyl-C(═O)—, 1-3 Alkyl, -C 1-3 Alkyl-O-, -C 1-3 Alkyl-S-, -C 1-3 Alkyl-NH- or -C 1-3 The compound according to claim 1 or 2, wherein alkyl-C(=O)- is optionally substituted by 1, 2 or 3 R, its optical isomers and its pharma- ceutically acceptable salts.

6. L 1 is a single bond, CH 2 , 【Chemistry 7】 wherein said CH 2 , 【change】 is optionally substituted by 1, 2 or 3 R, its optical isomers and pharma- ceutically acceptable salts thereof.

7. L 1 is a single bond, CH 2 , 【Chemistry 8】 The compound according to claim 6, its optical isomers and pharma- ceutically acceptable salts thereof, selected from:

8. L 2 is selected from a single bond, cyclobutyl, cyclopentyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl and 2,6-diazaspiro[3.3]heptyl, wherein said cyclobutyl, cyclopentyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl or 2,6-diazaspiro[3.3]heptyl is optionally substituted by one, two or three R, its optical isomers and pharma- ceutically acceptable salts thereof.

9. L 2 is a single bond, 【Chemistry 9】 The compound according to claim 8, its optical isomers and pharma- ceutically acceptable salts thereof, selected from:

10. L 3 is a single bond, C(=O), C 1-3 Alkyl, -C 1-3 Alkyl-C(=O)- and -C 1-3 alkyl-C(=O)NH-, 1-3 Alkyl, -C 1-3 Alkyl-C(=O)- or -C 1-3 3. The compound according to claim 1 or 2, wherein alkyl-C(=O)NH- is optionally substituted by 1, 2 or 3 R, its optical isomers and its pharma- ceutically acceptable salts.

11. L 3 is a single bond, C(=O), 【Chemistry 10】 The compound according to claim 10, its optical isomers and pharma- ceutically acceptable salts thereof, selected from:

12. R 1 NH 2 , 【Chemistry 11】 , C 1-3 Alkyl, cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, morpholinyl, piperidinyl, piperazinyl, octahydrocyclopentadiene [c]pyrrolyl, 4,5-dihydro-1H-imidazolyl, imidazolyl, 4,5-dihydro-1H-imidazolyl, imidazoline-2-imino, tetrahydropyranyl ... imidine-2(1H)-imino, 2,6-diazaspiro[3.3]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octyl, 6-oxa-2-azaspiro[3.4]octyl, 2,6-diazaspiro[3.4]octyl, 3,6-diazabicyclo[3.1.1]heptyl and 2,5-diazabicyclo[2.2.1]heptyl; 1-3 Alkyl, cyclopropylcyclobutyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, morpholinyl, piperidinyl, piperazinyl, octahydrocyclopentadiene[c]pyrrolyl, 4,5-dihydro-1H-imidazolyl, imidazolyl, 4,5-dihydro-1H-imidazolyl, imidazoline-2-imino, tetrahydropyrimidine-2(1H)-imino, 2,6-diazaspiro[3 3]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octyl, 6-oxa-2-azaspiro[3.4]octyl, 2,6-diazaspiro[3.4]octyl, 3,6-diazabicyclo[3.1.1]heptyl or 2,5-diazabicyclo[2.2.1]heptyl is optionally substituted by 1, 2 or 3 R, the compound according to claim 1 or 2, its optical isomers and pharma- ceutically acceptable salts thereof.

13. R 1 NH 2 , 【Chemistry 12】 wherein Me is selected from 【Chemistry 13】 is optionally substituted by 1, 2 or 3 R, its optical isomers and pharma- ceutically acceptable salts thereof.

14. R 1 NH 2 , Me., C.F. 3 , 【Chemistry 14】 The compound according to claim 13, its optical isomers and pharma- ceutically acceptable salts thereof, selected from:

15. Structural Units 【Chemistry 15】 ,Me,CF 3 , 【Chemistry 16】 【Chemistry 17】 15. The compound according to any one of claims 7, 9, 11 or 14, its optical isomers and pharma- ceutically acceptable salts thereof, selected from:

16. A compound represented by the following formula selected from the following formulae, its optical isomers and pharma- ceutically acceptable salts thereof: 【Chemistry 18】 【Chemistry 19】 【Chemistry 20】 【Chemistry 21】

17. A compound represented by the following formula selected from the following formulae, its optical isomers and pharma- ceutically acceptable salts thereof: 【Chemical 22】 【Chemistry 23】 【Chemistry 24】

18. 20. Use of a compound according to any one of claims 1 to 17, its optical isomers and pharma- ceutically acceptable salts thereof in the manufacture of a medicament for treating a bacterial infection.

19. The use according to claim 18, characterized in that it comprises a combination of a compound according to any one of claims 1 to 17, its optical isomers and its pharma-ceutically acceptable salts with another β-lactam antibiotic.

20. The use according to claim 19, characterized in that the β-lactam antibiotic is selected from penicillins, cephalosporins, carbapenems, monocyclic β-lactam antibiotics or combinations thereof.

21. The penicillins are selected from acid-resistant penicillins, enzyme-resistant penicillins, ampicillin, amoxicillin, pivampicillin, carbenicillin, sulfenicillin, ticarcillin, fulvencillin, azlocillin and piperacillin; Optionally, the cephalosporin is selected from cephalexin, cephradine, cefazolin, cefuroxime, cefamandole, cefaclor, cefotaxime, ceftazidime, ceftriazine, cefoperazone, ceftizoxime, cefepime, cefpirome, and ceftolozane; Optionally, the carbapenem is selected from imipenem, meropenem, panipenem, biapenem, ertapenem, and faropenem; 21. The use according to claim 20, optionally characterized in that the monocyclic β-lactam is selected from aztreonam.

Citation Information

Patent Citations

  • Boronic acid derivatives and their therapeutic uses

    JP2019527196A

  • Imine derivative

    WO2019009369A1

  • Novel substituted condensed ring compound

    WO2021079984A1